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ABSTRACT
The present invention relates to characterizing transcription
within cells. In particular, the present invention provides
transfected cell arrays (e.g., two-dimensional andlor threedimensional arrays) and systems, kits and methods utilizing
the same (e.g., f i r transcriptional activity characterization).
Compositions and methods of the present invention find use
in, among other things, research, drug discovery and clinical
(e.g., diagnostic, preventative and therapeutic) applications.

Patent Application Publication

May 8,2008 Sheet 11 of 11

FIGURE 11

US 200810108513 A1

May 8,2008

CELLULAR ARRAYS
[0001] The present invention claims priority to U.S. Provisional Patent Application Ser. Nos. 601810,102 and 601810,
110, filed Jun. 1,2006, each of which is hereby incorporated
by reference in its entirety.
[0002] This invention was made with government support
under contracts W81XWH-05-1-0381 awarded by the United
States Army Medical Research and Material Command (USAMRMC); R01 GM066830 and CA89018-03 awarded by
the National Institutes of Health; and BES0092701 awarded
by the National Science Foundation. The government has
certain rights in the invention.

FIELD OF THE INVENTION
[0003] The present invention relates to characterizing transcription within cells. In particular, the present invention provides transfected cell arrays (e.g., two-dimensional andor
three-dimensional arrays) and systems, kits and methods utilizing the same (e.g., for transcriptional activity characterization). Compositions and methods of the present invention find
use in, among other things, research, drug discovery and
clinical (e.g., diagnostic, preventative and therapeutic) applications.

BACKGROUND OF THE INVENTION
[0004] The human genome project has lead to an incredible
wealth of information regarding nucleic acid sequence. However, an emerging challenge is to identify gene products and
to determine the functional roles of the genes and gene products.

SUMMARY OF THE INVENTION
[0005] The present invention relates to characterizing transcription within cells. In particular, the present invention provides transfected cell arrays (e.g., two-dimensional andor
three-dimensional arrays) and systems, kits and methods utilizing the same (e.g., for transcriptional activity characterization). Compositions and methods of the present invention find
use in, among other things, research, drug discovery and
clinical (e.g., diagnostic, preventative and therapeutic) applications.
[0006] Accordingly, in some embodiments, the present
invention provides a composition comprising a three-dimensional transfection cell array comprising an array of spatially
controllable immobilized gels, wherein the gels comprise a
crosslinkable biopolymer solution comprising cells exposed
to transfection molecules. In some embodiments, the gels
- are
formed by adding a solution comprising transfection molecules and cells to a crosslinkable biopolymer (e.g., alginate)
solution, allowing beads to form, and placing the same within
cell growth media. In some embodiments, the crosslinkable
biopolymer solution comprises alginate and collagen. the
present invention is not limited to any particular crosslinkable
biopolymer solution. Indeed, a variety of crosslinkable
biopolymer solutions are contemplated to be useful in the
compositions and methods of the present invention including,
but not limited to, acrylated poly(ethy1ene glycol) (PEGAcry1)hydrogels and other biopolymer solutions described
herein. In some embodiments, the composition further comprises a charge neutralizing reagent (e.g., polyethyleimine
(PEI)). In some embodiments, the alginate is present at a final

concentration of about 1.5%, although higher and lower percentages may be used (e.g., as described herein). In some
embodiments, the collagen is present at a final concentration
of about 0.2%, although higher and lower percentages may be
used (e.g.,
- as described herein) In some embodiments, PEI is
present in an amount such that the nitrogen to phosphate ratio
is 25. In some embodiments. the transfection molecules are
nucleic acid sequences. In some embodiments, the nucleic
acid sequences are located within expression vectors. In some
embodiments, the transfection molecules comprise a normalization plasmid and a functional plasmid. In some embodiments, the normalization plasmid comprises a promoter
region and a reporter molecule that allows cellular transfection efficiency to be normalized over the array. In some
embodiments, the functional plasmid comprises a reporter
molecule that is different from the reporter molecule of the
normalization plasmid. The present invention is not limited
by the type of reporter molecules utilized. Indeed, a variety of
reporter molecules are described herein including, but not
limited to, various luciferase reporters and fluorescentreporters (e.g., green fluorescent protein reporters).
[0007] In some embodiments, the present invention also
provides, a method of transfecting cells comprising providing: a composition comprising a biopolymer comprising alginate and collagen,
- transfection molecules, and cells; and mixing the composition comprising biopolymer, transfection
molecules and cells, in the presence of PEI, under conditions
such that beads form; and placing the beads in cell growth
media.
[0008] Embodiments of the present invention also provide
a method of generating an array, comprising: forming holes in
a first material to generate an array mold, attaching the array
mold to a solid substrate to form a complex comprising a
plurality ofwells; depositing first nucleic acid vectors into the
plurality of wells under conditions such that the first nucleic
acidvectors are generally immobilized on the solid substrate,
wherein the first nucleic acid vectors comprise nucleic acid
sequences, and removing the array mold from the solid substrate to generate an array on the solid substrate. In some
embodiments, the nucleic acid sequences comprise a reporter
gene; andor a promoter region configured to bind transcription factors. The present invention also provides arrays (e.g.,
two-dimensional transfection cell arrays) generated according to such a method. In some embodiments, the first material
comprises PDMS. In some embodiments, the solid substrate
comprises polystyrene. In some embodiments, method further comprises depositing second nucleic acidvectors into the
plurality of wells, wherein the second nucleic acid vectors
comprise nucleic acid comprising: 1) a second reporter gene;
and 2) a promoter region that allows transfection efficiency to
be normalized (e.g., relative to transcriptional activity) over
the array. In some embodiments, the first nucleic acid vectors
are immobilized on the solid substrate such that they can
deliver the nucleic acid to a cell.
~

DESCRIPTION OF THE DRAWINGS
[0009] FIG. 1 shows a multiwell dish format reporter gene
assay to compare surface delivery to traditional bolus delivery. Surface delivery (B) of ERE reporter plasmid system
(pERE(3X)TK-ffLUC and normalization plasmid pTKrLUC) resulted in E2-stimulatedtranscriptional responses in
MCF-7 breast cancer cells similar to bolus delivery (A),
reported as a ratio of firefly to renilla luciferase, with E2
statistically inducing firefly luciferase expression 6-7 fold
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over vehicle control or the addition of FUL. Columns labeled
with same letter designate conditions not statistically different; all other comparisons, p<0.001.
[0010] FIG. 2 shows the effect of DNA amount on E, activation of ERE reporter plasmid system (pERE(3X)TKffLUC and normalization plasmid pTK-rLUC) delivered to
MCF-7 breast cancer cells. Total amount of DNA added to the
surface (B) or delivered as a bolus (A), in the presence of 1oP9
M E,, resulted in a similar dose-response effect. Columns
labeled with same letter designate conditions not statistically
different; all other comparisons, p<0.01 for (A), p<0.05 for
(B).
[0011] FIG. 3 shows the effect of complexing agent and E,
dose response on the ERE reporter plasmid system (pERE
(3 X)TK-ffLUC and normalization plasmid pTK-rLUC).
Bolus and surface delivery of Lipofectamine 2000 complexes
(A) resulted in induction profiles that were not statistically
different from each other, for each concentration of E,. Bolus
delivery of Effectene complexes (B) resulted in statistically
higher induction (p<0.05) than surface delivery for all concentrations of E,, except control, however surface delivery
resulted in more statistically different induction responses.
Columns labeled with same letter designate conditions not
statistically different; all other comparisons, p<0.05.
[0012] FIG. 4 shows array fabricationwith soft lithography
techniques to pattern DNA-lipid complex deposition and
transfection. A polydimethylsiloxane (PDMS) mold (A) was
reversibly sealed to polystyrene slides (B), so that the holes in
the mold, termed microwells, served as reservoirs for deposition of DNA complexes onto the polystyrene (C). After
complex deposition in the microwells, the PDMS mold was
peeled away from the polystyrene slide, which was then
rinsed thoroughly. Rhodamine-labeled DNA complexes were
immobilized on the slide in distinct regions, replicating the
pattern of microwells in the PDMS mold (D-F). Transfection
of MCF-7 cells seeded onto these arrays of patterned complexes on polystyrene slides was also confined to thepatterns,
as determined by GFP expression (G-I).
[0013] FIG. 5 shows bioluminescence imaging to detect
dual-luciferase expression in an array format. Transfection of
MCF-7 cells seeded onto arrays of complexes was assayed
after 24 hours by sequentially adding the renilla and firefly
luciferase substrates. The renilla substrate, VIVIREN (10
pM), was first added into the media and the array was imaged
to determine pTK-rLUC expression (A). D-Luciferin (1 mM)
was subsequently added to the same array, which was then
imaged to acquire a dual signal (B). Firefly luciferase expression (pLUC) was determined by subtracting the VIVIREN
signal from the signal obtained through imaging with the
D-luciferin. When normalized, the firefly luciferase signal
was 34? 8 fold greater than the respective renilla expression.
[0014] FIG. 6 shows arrays used to monitor ERa induction
of transcriptional activity. Complexes formed with different
plasmids were immobilized in different spots of the array, as
follows: 1. pLUC, 2. none, 3. pERE(3 X)TK-ffLUC, 4. pERE
(3X)TK-ffLUC and pTK-rLUC (2:l ratio), and 5. pPGAL.
Cells seeded on the arrays were treated with combinations of
ethanol control (A-B), E, (C-D), or E, plus FUL (E-F). Dualluciferase levels were analyzed 24 hours later with bioluminescence imaging, by first imaging with the renilla luciferase
substrate, VIVIREN (A, C, E) and then imaging each array
with D-luciferin, the firefly luciferase substrate (B, E, F).
Induction of the ERE-regulated plasmid system was calculated by normalizing firefly luciferase expression to renilla

luciferase expression (G). Firefly luciferase expression was
determined by subtracting the VIVIREN signal from the signal obtained through imaging with the D-luciferin. For spots
containing both the pERE(3 X)TK-ffLUC and pTK-rLUC
plasmids (column4), E, statistically inducedfirefly luciferase
expression 10-fold over control or FUL conditions, reported
as a ratio of firefly to renilla luciferase (G). Columns labeled
with same letter designate conditions not statistically different; all other comparisons, p<0.001.
[0015] FIG. 7 shows concentration response of E, on the
ERE reporter plasmid system in an array format. For spots
containing both the pERE(3 X)TK-ffLUC and pTK-rLUC
plasmids, increasing the concentration of E, statistically
increased the induction of firefly luciferase expression, verifying a true concentration-response of E, in the induction of
this plasmid system in an array format. Columns labeled with
same letter designate conditions not statistically different; all
other comparisons, p<0.05.
[0016] FIG. 8 shows phase imaging of 1.5% alginate beads
(a) before MTT staining (control), (b and c) after MT'T staining after 24 and 48 hr., and (d and e) imaging of beads
containing 1.5% alginate and 0.2% collagen stained after 24
and 48 hr.
[0017] FIG. 9 shows transfection efficiency for MCF-7
cells as a function of (a) N:P ratio and (b) DNA concentration
as determined by beta-galactosidase staining.
[0018] FIG. 10 shows phase images of alginate beads containing MCF-7 cells transfected with beta-galactosidase.
DNA Beta-gal staining of cells occurred 1,2, and 3 days after
initial incubation (a, b, and c). Transfected cells appear darkly
stained.
[0019] FIG. 11 shows luciferase expression in array in
terms of photon flux.
DEFINITIONS
[0020] To facilitate an understanding of the invention, a
number of terms are defined below.
[0021] As used herein, the term "transfection molecule"
refers to a molecule that is transfected (e.g., via placid andor
viral means) into a host cell (e.g., within a transfection cell
array described herein). The molecule transfected may be a
nucleic acid that is of interest with respect to its ability to
confer a change in the phenotype of the host cells (e.g., alter
transcription, translation, cell cycle, etc.). The molecule
transfected mav refer to a nucleic acid seauence that varies
from one portion of an array to the next. The molecule transfected may also include plasmid andor viral sequence.
Nucleic acid sequences that are transfected may be coding
sequences for a protein, or for an RNA molecule (e.g., which
is transcribed into an anti-sense RNA sequence, a ribozyme or
double-stranded RNA, etc.), or a regulatory sequence (e.g., as
part of a reporter construct), or other type of sequence.
[0022] As used herein, the terms "spot" and "transfection
zone." refers to the location within an arrav that cells are
exposed to transfection molecules. The location may be
within a 2-D array or 3-D array. Within a 2-D array, a "spot"
or "transfection zone" generally refers to a location where a
transfection molecule is immobilized to a substrate surface.
Within a 3-D arrav.
a , a "snot" or "transfection zone" refers
generally to regions where polymeric-mediated delivery of
transfection molecules to cells occurs.
[0023] As used herein, the term "gene transfer system"
refers to any means of delivering a composition comprising a
nucleic acid sequence to a cell or tissue. For example, gene
L
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transfer systems include, but are not limited to, vectors (e.g.,
retroviral, adenoviral, adeno-associated viral, and other
nucleic acid-based delivery systems), microinjection of
naked nucleic acid, polymer-based delivery systems (e.g.,
liposome-based and metallic particle-based systems), biolistic injection, and the like. As used herein, the term "viral gene
transfer system" refers to gene transfer systems comprising
viral elements (e.g., intact viruses, modified viruses and viral
components such as nucleic acids or proteins) to facilitate
delivery of a sample (e.g., a nucleic acid encoding a fusion
protein of the present invention) to a desired cell or tissue. As
used herein, the term "adenovirus gene transfer system"
refers to gene transfer systems comprising intact or altered
viruses belonging to the family Adenoviridae.
[0024] As used herein, the term "site-specific recombination target sequences" refers to nucleic acid sequences that
provide recognition sequences for recombination factors and
the location where recombination takes place.
[0025] As used herein, the term "nucleic acid molecule"
refers to any nucleic acid containing molecule, including but
not limited to, DNA or RNA. The term encompasses
sequences that include any of the known base analogs of DNA
and RNA including, but not limited to, 4-acetylcytosine,
8-hydroxy-N-6-methyladenosine,
aziridinylcytosine,

5-carboxymethylaminomethyluracil,
ethyl-2-thiouracil,
dihydrouracil, inosine, N6-isopentenyladenine, 1-methyladenine, 1-methylpseudouracil, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine,
3-methylcytosine,
5-methylcytosine,
N6-methyladenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxy-aminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5oxyacetic acid methylester, uracil-5-oxyacetic acid,
oxybutoxosine, pseudouracil, queosine, 2-thiocytosine,
5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid, pseudouracil, queosine, 2-thiocytosine, and 2,6diaminopurine.
[0026] The term "gene" refers to a nucleic acid (e.g., DNA)
sequence that comprises coding sequences necessary for the
production of a polypeptide, RNA (e.g., including but not
limited to, mRNA, tRNA and rRNA) or precursor. The
polypeptide, RNA, or precursor can be encoded by a full
length coding sequence or by any portion thereof. The term
also encompasses the coding region of a structural gene and
the sequences located adjacent to the coding region on both
the 5' and 3' ends for a distance of about 1 kb on either end
such that the gene corresponds to the length of the full-length
mRNA. The sequences that are located 5' of the coding region
and which are present on the mRNA are referred to as 5'
untranslated sequences. The sequences that are located 3' or
downstream of the coding region and that are present on the
mRNA are referred to as 3' untranslated sequences. The term
"gene" encompasses both cDNA and genomic forms of a
gene. A genomic form or clone of a gene contains the coding
region interrupted with non-coding sequences termed
"introns" or "intervening regions" or "intervening
sequences." Introns are segments of a gene that are transcribed into nuclear RNA (hnRNA); introns may contain
regulatory elements such as enhancers. Introns are removed
or "spliced out" from the nuclear or primary transcript;

introns therefore are absent in the messenger RNA (mRNA)
transcript. The mRNA functions during translation to specify
the sequence or order of amino acids in a nascent polypeptide.
[0027] Where "amino acid sequence" is recited herein to
refer to an amino acid sequence of a naturally occurring
protein molecule, "amino acid sequence" and like terms, such
as "polypeptide" or "protein" arenot meant to limit the amino
acid sequence to the complete, native amino acid sequence
associated with the recited protein molecule.
[0028] In addition to containing introns, genomic forms of
a gene may also include sequences located on both the 5' and
3' end of the sequences that are present on the RNA transcript.
These sequences are referred to as "flanking" sequences or
regions (these flanking sequences are located 5' or 3' to the
non-translated sequences present on the mRNA transcript).
The 5' flanking region may contain regulatory sequences such
as vromoters and enhancers that control or influence the transcription of the gene. The 3' flanking region may contain
sequences that direct the termination of transcription, posttranscriptional cleavage and polyadenylation.
[0029] The term "wild-type" refers to a gene or gene product that has the characteristics of that gene or gene product
when isolated from a naturally occurring source. A wild-type
gene is that which is most frequently observed in a population
and is thus arbitrarily designed the "normal" or "wild-type"
form of the gene. In contrast, the terms "modified," "mutant,"
"polymorphism," and "variant" refer to a gene or gene product that displays modifications in sequence andor functional
properties (i.e., altered characteristics) when compared to the
wild-type gene or gene product. It is noted that naturallyoccurring mutants can be isolated; these are identified by the
fact that they have altered characteristics (e.g., increased or
decreased solubility) when compared to the wild-type gene or
gene product.
[0030] As used herein, the terms "nucleic acid molecule
encoding," "DNA sequence encoding," and "DNA encoding"
refer to the order or sequence of deoxyribonucleotides along
a strand of deoxyribonucleic acid. The order of these deoxyribonucleotides determines the order of amino acids along
the polypeptide (protein) chain. The DNA sequence thus
codes for the amino acid sequence.
[0031] As used herein, the term "heterologous gene" refers
to a gene that is not in its natural environment. For example,
a heterologous gene includes a gene from one species introduced into another species.A heterologous gene also includes
a gene native to an organism that has been altered in some way
(e.g., mutated, added in multiple copies, linked to non-native
regulatory sequences, etc.). Heterologous genes are distinguished from endogenous genes in that the heterologous gene
sequences are typically joined to DNA sequences that are not
found naturally associated with the gene sequences in the
chromosome or are associated with portions of the chromosome not found in nature (e.g., genes expressed in loci where
the gene is not normally expressed).
[0032] DNA molecules are said to have "5' ends" and "3'
ends" because mononucleotides are reacted to make oligonucleotides or polynucleotides in a manner such that the 5'
phosphate of one mononucleotide pentose ring is attached to
the 3' oxygen of its neighbor in one direction via a phosphodiester linkage. Therefore, an end of an oligonucleotides or
polynucleotide, referred to as the "5' end" if its 5' phosphate is
not linked to the 3' oxygen of a mononucleotide pentose ring
and as the "3' end" if its 3' oxygen is not linked to a 5'
phosphate of a subsequent mononucleotide pentose ring. As
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used herein, a nucleic acid sequence, even if internal to a
larger oligonucleotide or polynucleotide, also may be said to
have 5' and 3' ends. In either a linear or circular DNA molecule, discrete elements are referred to as being "upstream" or
5' of the "downstream" or 3' elements. This terminology
reflects the fact that transcription proceeds in a 5' to 3' fashion
along the DNA strand. The promoter and enhancer elements
that direct transcription of a linked gene are generally located
5' or upstream of the coding region. However, enhancer elements can exert their effect even when located 3' of the promoter element and the coding region. Transcription terminationandpolyadenylation signals are located3' or downstream
of the coding region.
[0033] In addition to containing introns, genomic forms of
a gene may also include sequences located on both the 5' and
3' end of the sequences that are present on the RNA transcript.
These sequences are referred to as "flanking" sequences or
regions (these flanking sequences are located 5' or 3' to the
non-translated sequences present on the mRNA transcript).
The 5' flanking region may contain regulatory sequences such
as promoters and enhancers that control or influence the transcription of the gene. The 3' flanking region may contain
sequences that direct the termination of transcription, posttranscriptional cleavage and polyadenylation.
[0034] As used herein, the terms "an oligonucleotide having a nucleotide sequence encoding a gene" and "polynucleotide having a nucleotide sequence encoding a gene," means
a nucleic acid sequence comprising the coding region of a
gene or, in other words, the nucleic acid sequence that
encodes a gene product. The coding region may be present in
a cDNA, genomic DNA, or RNA form. When present in a
DNA form, the oligonucleotide or polynucleotide may be
single-stranded (i.e., the sense strand) or double-stranded.
Suitable control elements such as enhancers/promoters,
splice junctions, polyadenylation signals, etc. may be placed
in close proximity to the coding region of the gene if needed
to permit proper initiation of transcription andor correct processing of the primary RNA transcript. Alternatively,the coding region utilized in the expression vectors of the present
invention may contain endogenous enhancers/promoters,
splice junctions, intervening sequences, polyadenylation signals, etc. or a combination of both endogenous and exogenous
control elements.
[0035] As used herein, the term "regulatory element" refers
to a genetic element that controls some aspect of the expression of nucleic acid sequences. For example, a promoter is a
regulatory element that facilitates the initiation of transcription of an operably linked coding region. Other regulatory
elements include splicing signals, polyadenylation signals,
termination signals, etc.
[0036] As used herein, the terms "complementary" or
"complementarity" are used in reference to polynucleotides
(i.e., a sequence of nucleotides) related by the base-pairing
rules. For example, the sequence 5'-A-G-T-3',is complementary to the sequence 3'-T-C-A-5'. Complementarity may be
"partial," in which only some of the nucleic acids' bases are
matched according to the base pairing rules. Or, there may be
"complete" or "total" complementarity between the nucleic
acids. The degree of complementarity between nucleic acid
strands has significant effects on the efficiency and strength of
hybridization between nucleic acid strands. This is of particular importance in amplificationreactions, as well as detection
methods that depend upon binding between nucleic acids.
Complementarity can include the formation of base pairs

between any type of nucleotides, including non-natural bases,
modified bases, synthetic bases and the like.
[0037] The term "homology" refers to a degree of complementarity. There may be partial homology or complete
homology (i.e., identity). A partially complementary
sequence is one that at least partially inhibits a completely
complementary sequence from hybridizing to a target nucleic
acid and is referred to using the functional term "substantially
homologous." The term "inhibition of binding," when used in
reference to nucleic acid binding, refers to inhibition of binding caused by competition of homologous sequences for
binding to a target sequence. The inhibition of hybridization
of the completely complementary sequence to the target
sequence may be examined using a hybridization assay
(Southern or Northern blot, solution hybridization and the
like) under conditions of low stringency. A substantially
homologous sequence or probe will compete for and inhibit
the binding (i.e., the hybridization) of a completely homologous to a target under conditions of low stringency.This is not
to say that conditions of low stringency are such that nonspecific binding is permitted; low stringency conditions
require that the binding of two sequences to one another be a
specific (i.e., selective) interaction. The absence of non-specific binding may be tested by the use of a second target that
lacks even a partial degree of complementarity (e.g., less than
about 30% identity); in the absence of non-specific binding
the probe will not hybridize to the second non-complementary target.
[0038] The art knows well that numerous equivalent conditions may be employed to comprise low stringency conditions; factors such as the length and nature (DNA, RNA, base
composition) of the probe and nature of the target (DNA,
RNA, base composition, present in solution or immobilized,
etc.) and the concentration of the salts and other components
(e.g., the presence or absence of formamide, dextran sulfate,
polyethylene glycol) are considered and the hybridization
solution may be varied to generate conditions of low stringency hybridization different from, but equivalent to, the
above listed conditions. In addition, the art knows conditions
that promote hybridization under conditions of high
- stringency (e.g., increasing the temperature of the hybridization
andor wash steps, the use of formamide in the hybridization
solution, etc.).
[0039] Whenusedinreference to a double-strandednucleic
acid sequence such as a cDNA or genomic clone, the term
"substantially homologous" refers to any probe that can
hybridize to either or both strands of the double-stranded
nucleic acid sequence under conditions of low stringency as
described above.
[0040] A gene may produce multiple RNA species that are
generated by differential splicing of the primary RNA transcript. cDNAs that are splice variants of the same gene will
contain regions of sequence identity or complete homology
(representing the presence of the same exon or portion of the
same exon on both cDNAs) and regions of complete nonidentity (for example, representing the presence of exon "A'"
on cDNA 1 wherein cDNA 2 contains exon "B" instead).
Because the two cDNAs contain regions of sequence identity
they will both hybridize to a probe derived from the entire
gene or portions of the gene containing sequences found on
both cDNAs; the two splice variants are therefore substantially homologous to such a probe and to each other.
[0041] When used in reference to a single-stranded nucleic
acid sequence, the term "substantially homologous" refers to
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any probe that can hybridize (i.e., it is the complement of) the
single-stranded nucleic acid sequence under conditions of
low stringency as described above.
[0042] As used herein, the term "hybridization" is used in
reference to the pairing of complementary nucleic acids.
Hybridization and the strength of hybridization (i.e., the
strength
- of the association between the nucleic acids) is
impacted by such factors as the degree of complementary
between the nucleic acids. strinaencv of the conditions
involved, the T, of the formed h;brii, and the G:C ratio
within the nucleic acids.
[0043] As used herein, the term "T," is used in reference to
the "melting temperature." The melting temperature is the
temperature at which a population of double-stranded nucleic
acid molecules becomes half dissociated into single strands.
The equation for calculating the T, of nucleic acids is well
known in the art. As indicated bv standard references. a
simple estimate of the T, value may be calculated by the
equation: T,=81 .5 +0.41 (% G+C), when anucleic acidis in
aqueous solution at 1 M NaCl (See e.g., Anderson andyoung,
Quantitative Filter Hybridization, in Nucleic Acid Hybridization (1985)). Other references include more sophisticated
computations that take structural as well as sequence characteristics into account for the calculation of T,.
[0044] As used herein the term "stringency" is used in
reference to the conditions of temperature, ionic strength, and
the presence of other compounds such as organic solvents,
under which nucleic acid hybridizations are conducted.
Those skilled in the art will recognize that "stringency" conditions may be altered by varying the parameters just
described either individually or in concert. With "high stringency" conditions, nucleic acid base pairing will occur only
between nucleic acid fragments that have a high frequency of
complementary base sequences (e.g., hybridization under
"high stringency" conditions may occur between homologs
with about 85-100% identity, preferably about 70-100%
identity). With medium stringency conditions, nucleic acid
base -pairing
- will occur between nucleic acids with an intermediate frequency of complementary base sequences (e.g.,
hybridization under "medium stringency" conditions may
occur between homologs with about 50-70% identity). Thus,
conditions of "weak" or "low" stringency are often required
with nucleic acids that are derived from organisms that are
genetically diverse, as the frequency of complementary
sequences is usually less. "High stringency conditions" when
used in reference to nucleic acid hybridization comprise conditions equivalent to binding or hybridization at 42' C. in a
solution consisting of 5XSSPE (43.8 gll NaCl, 6.9 g/l
NaH2P04H20 and 1.85 g/l EDTA, pH adjusted to 7.4 with
NaOH), 0.5% SDS, 5 XDenhardt's reagent and 100 pg/ml
denatured salmon sperm DNA followed by washing in a
solution comprising 0.1 XSSPE, 1.O% SDS at 42' C. when a
probe of about 500 nucleotides in length is employed.
[0045] "Medium stringency conditions" when used in reference to nucleic acid hybridization comprise conditions
equivalent to binding or hybridization at 42' C. in a solution
consisting of 5XSSPE (43.8 gll NaCl, 6.9 g/l NaH2P04H20
and 1.85 gll EDTA, pH adjusted to 7.4 with NaOH), 0.5%
SDS, 5 XDenhardt's reagent and 100 pglml denatured salmon
sperm DNA followed by washing in a solution comprising
1.OXSSPE, 1.O% SDS at 42" C. when a probe of about 500
nucleotides in length is employed.
[0046] "Low stringency conditions" comprise conditions
equivalent to binding or hybridization at 42' C. in a solution

consisting of 5 XSSPE (43.8 gll NaCl, 6.9 gll NaH2P04H20
and 1.85 gll EDTA, pH adjusted to 7.4 with NaOH), 0.1%
SDS, 5XDenhardt's reagent (5OXDenhardt's contains per
500 ml: 5 g Ficoll (Type 400, Pharamcia), 5 g BSA (Fraction
V, Sigma)) and 100 pglml denatured salmon sperm DNA
followed by washing ina solutioncomprising 5 X SSPE, 0.1%
SDS at 42" C. whena probe of about 500nucleotides in length
is employed.
[0047] The art knows well that numerous equivalent conditions may be employed to comprise low stringency conditions; factors such as the length and nature (DNA, RNA, base
composition) of the probe and nature of the target (DNA,
RNA, base composition, present in solution or immobilized,
etc.) and the concentration of the salts and other components
(e.g., the presence or absence of formamide, dextran sulfate,
polyethylene glycol) are considered and the hybridization
solution may be varied to generate conditions of low stringency hybridization different from, but equivalent to, the
above listed conditions. In addition, the art knows conditions
that vromote hybridization under conditions of high stringency (e.g., increasing the temperature of the hybridization
andor wash stens. the use of formamide in the hvbridization
solution, etc.) (see definition above for "stringency").
[0048] The term "fragment" as used herein refers to a
polypeptide that has an amino-terminal andor carboxy-terminal deletion as compared to the native protein, but where
the remaining amino acid sequence is identical to the corresponding positions in the amino acid sequence deduced from
a full-length cDNA sequence. Fragments typically are at least
4 amino acids long, preferably at least 20 amino acids long,
usually at least 50 amino acids long or longer, and span the
portion of the polypeptide required for intermolecular binding of the compositions (claimed in the present invention)
with its various ligands andor substrates.
[0049] The term "naturally-occurring" as used herein as
applied to an object refers to the fact that an object can be
found in nature. For example, a polypeptide or polynucleotide
sequence that is present in an organism (including viruses)
that can be isolated from a source in nature and which has not
been intentionally modified by man in the laboratory is naturally-occurring.
[0050] As used herein, the term "recombinant DNA molecule" as used herein refers to a DNA molecule that is comprised of segments of DNA joined together by means of
molecular biological techniques.
[0051] As used herein, the term "antisense" is used in reference to RNA sequences that are complementary to a specific RNA sequence (e.g., mRNA). Included within this definition are antisense RNA ("asRNA") molecules involved in
gene regulation by bacteria. Antisense RNA may be produced
by any method, including synthesis by splicing the gene(s) of
interest in a reverse orientation to a viral promoter that permits the synthesis of a coding strand. Once introduced into an
embryo, this transcribed strand combines withnatural mRNA
produced by the embryo to form duplexes. These duplexes
then block either the further transcription of the mRNA or its
translation. In this manner, mutant phenotypes may be generated. The term "antisense strand" is used in reference to a
nucleic acid strand that is complementary to the "sense"
strand. The designation (-) (i.e., "negative") is sometimes
used in reference to the antisense strand, with the designation
(+) sometimes used in reference to the sense (i.e., "positive")
strand.
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[0052] As used herein the term "coding region" when used
in reference to a structural gene refers to the nucleotide
sequences that encode the amino acids found in the nascent
polypeptide as a result of translation of a mRNA molecule.
The coding region is bounded, in eukaryotes, on the 5' side by
the nucleotide triplet "ATG" that encodes the initiator
methionine and on the 3' side by one of the three triplets,
which specify stop codons (i.e., TAA, TAG, TGA).
[0053] As used herein the term "portion" when in reference
to a nucleotide sequence (as in "a portion of a given nucleotide sequence") refers to fragments of that sequence. The
fragments may range in size from four nucleotides to the
entire nucleotide sequence minus one nucleotide (e.g., 10
nucleotides, 20,30,40, 50, 100, 200, etc.).
[0054] As used herein, the terms "restriction endonucleases" and "restriction enzymes" refer to bacterial
enzymes, each of which cut double-stranded DNA at or near
a specific nucleotide sequence.
[0055] The terms "in operable combination," "in operable
order," and "operably linked" as used herein refer to the
linkage of nucleic acid sequences in such a manner that a
nucleic acidmolecule capable of directing the transcription of
a given gene andor the synthesis of a desired protein molecule is produced. The term also refers to the linkage of amino
acid seauences in such a manner so that a functional nrotein is
produced. The present invention is not limited to naturally
occurring protein molecules. For example, the present invention contemplates synthesis of fusion proteins comprising
multiple regions of unique polypeptide sequences (e.g., a Tat
leader sequence, a target protein sequence, and marker protein sequence).
[0056] The term "isolated" when used in relation to a
nucleic acid, as in "an isolated oligonucleotide" or "isolated
polynucleotide" refers to a nucleic acid sequence that is identified and separated from at least one component or contaminant with which it is ordinarilv associated in its natural
source. Isolated nucleic acid is such present in a form or
setting that is different from that in which it is found innature.
In contrast, non-isolated nucleic acids are nucleic acids such
as DNA and RNA found in the state they exist in nature. For
example, a given DNA sequence (e.g., a gene) is found on the
host cell chromosome in proximity to neighboring genes;
RNA sequences, such as a specific mRNA sequence encoding
a specific protein, are found in the cell as a mixture with
numerous other mRNAs that encode a multitude of proteins.
However, isolated nucleic acid encoding a given protein
includes, by way of example, such nucleic acid in cells ordinarily expressing the given protein where the nucleic acid is in
a chromosomal location different from that of natural cells, or
is otherwise flanked by a different nucleic acid sequence than
that found in nature. The isolated nucleic acid., olinonucleu
otide, or polynucleotide may be present in single-stranded or
double-stranded form. When an isolated nucleic acid, oligonucleotide or polynucleotide is to be utilized to express a
protein, the oligonucleotide or polynucleotide will contain at
a minimum the sense or coding strand (i.e., the oligonucleotide or polynucleotide may be single-stranded), but may
contain both the sense and anti-sense strands (i.e., the oligonucleotide or polynucleotide may be double-stranded).
[0057] As used herein, the term "purified" or "to purify"
refers to the removal of components (e.g., contaminants)
from a sample. For example, antibodies are purified by
removal of contaminating non-immunoglobulin proteins;
they are also purified by the removal of immunoglobulin that
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does not bind to the tarnet molecule. The removal of nonimmunoglobulin proteins andor the removal of immunoglobulins that do not bind to the target molecule results in an
increase in the percent of target-reactive immunoglobulins in
the sample. In another example, recombinant polypeptides
are expressed in bacterial host cells and the polypeptides are
purified by the removal of host cell proteins; the percent of
recombinant polypeptides is thereby increased in the sample.
[0058] As used herein, the term "native protein" is used to
indicate that a protein does not contain amino acid residues
encoded by vector sequences; that is, the native protein contains only those amino acids found in the protein as it occurs
in nature. A native protein may be produced by recombinant
means or may be isolated from a naturally occurring source.
[0059] As used herein the term "portion" when in reference
to a protein (as in "a portion of a given protein") refers to
fragments of that protein. The fragments may range in size
from four amino acid residues to the entire amino acid
sequence minus one amino acid.
[0060] The term "Southern blot," refers to the analysis of
DNA on agarose or acrylamide gels to fractionate the DNA
accordinn
u to size followed bv transfer of the DNA from the
gel to a solid support, such as nitrocellulose or a nylon membrane. The immobilized DNA is then probed with a labeled
probe to detect DNA species complementary to the probe
used. The DNA may be cleaved with restriction enzymes
prior to electrophoresis. Following electrophoresis, the DNA
may be partially depurinated and denatured prior to or during
transfer to the solid support. Southern blots are a standard tool
of molecular biologists (J. Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press, NY, pp
9.31-9.58 (1989)).
[0061] The term "Northern blot," as used herein refers to
the analysis of RNA by electrophoresis of RNA on agarose
gels to fractionate the RNA according to size followed by
transfer of the RNA from the gel to a solid support, such as
nitrocellulose or a nylon membrane. The immobilized RNA is
then probed with a labeled probe to detect RNA species
complementary to the probe used. Northern blots are a standard tool of molecular biologists (J. Sambrook, et al., supra,
pp 7.39-7.52 (1989)).
[0062] The term "Western blot" refers to the analysis of
protein(s) (or polypeptides) immobilized onto a support such
as nitrocellulose or a membrane. The proteins are run on
acrylamide gels to separate the proteins, followed by transfer
of the protein from the gel to a solid support, such as nitrocellulose or a nvlon membrane. The immobilizednroteins are
then exposed to antibodies with reactivity against an antigen
of interest. The binding of the antibodies may be detected by
various methods, including the use of radiolabeled antibodies.
[0063] The term "transgene" as used herein refers to a
foreign gene that is placed into an organism by, for example,
introducing the foreign gene into newly fertilized eggs or
early embryos. The term "foreign gene" refers to any nucleic
acid (e.g., gene sequence) that is introduced into the genome
of an animal by experimental manipulations and may include
gene sequences found in that animal so long as the introduced
gene does not reside in the same location as does the naturally
occurring gene.
[0064] As used herein, the term "vector" is used in reference to nucleic acid molecules that transfer DNA segment(s)
from one cell to another. The term "vehicle" is sometimes
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used interchangeably with "vector." Vectors are often derived
from plasmids, bacteriophages, or plant or animal viruses.
[0065] The term "expression vector" as used herein refers
to a recombinant DNA molecule containing a desired coding
sequence and appropriate nucleic acid sequences necessary
for the expression of the operably linked coding sequence in
a particular host organism. Nucleic acid sequences necessary
for expression in prokaryotes usually include a promoter, an
operator (optional), and a ribosome binding site, often along
with other sequences. Eukaryotic cells are known to utilize
promoters, enhancers, and termination and polyadenylation
signals.
[0066] The terms "overexpression" and "overexpressing"
and grammatical equivalents, are used in reference to levels of
mRNA to indicate a level of expression approximately 3-fold
higher (or greater) than that observed in a given tissue in a
control or non-transgenic animal. Levels of mRNA are measured using any of a number of techniques known to those
skilled in the art including, but not limited to Northern blot
analysis. Appropriate controls are included on the Northern
blot to control for differences in the amount of RNA loaded
from each tissue analyzed (e.g., the amount of 28s rRNA, an
abundant RNA transcript present at essentially the same
amount in all tissues, present in each sample can be used as a
means of normalizing or standardizing the mRNA-specific
signal observed on Northern blots). The amount of mRNA
present in the band corresponding in size to the correctly
spliced transgene RNA is quantified; other minor species of
RNA which hybridize to the transgene probe are not considered in the quantification of the expression of the transgenic
mRNA.
[0067] The term "transfection" as used herein refers to the
introduction of foreign DNA into eukaryotic cells. Transfectionmay be accomplished by a variety of means known to the
art including calcium phosphate-DNA co-precipitation,
DEAE-dextran-mediated transfection, polybrene-mediated
transfection, electroporation, microinjection, liposome
fusion, lipofection, protoplast fusion, retroviral infection, and
biolistics.
[0068] The term "calcium phosphate co-precipitation"
refers to a technique for the introduction of nucleic acids into
a cell. The uptake of nucleic acids by cells is enhanced when
the nucleic acid is presented as a calcium phosphate-nucleic
acid co-precipitate. The original technique of Graham and
van der Eb (Graham and van der Eb, Virol., 52:456 (1973)),
has been modified by several groups to optimize conditions
for particular types of cells. The art is well aware of these
numerous modifications.
[0069] The term "stable transfection" or "stably transfected" refers to the introduction and integration of foreign
DNA into the genome of the transfected cell. The term "stable
transfectant" refers to a cell that has stably integrated foreign
DNA into the genomic DNA.
[0070] The term "transient transfection" or "transiently
transfected" refers to the introduction of foreign DNA into a
cell where the foreign DNA fails to integrate into the genome
of the transfected cell. The foreign DNA persists in the
nucleus of the transfected cell for several days. During this
time the foreign DNA is subject to the regulatory controls that
govern the expression of endogenous genes in the chromosomes. The term "transient transfectant" refers to cells that
have taken up foreign DNA but have failed to integrate this
DNA.

[0071] As used herein, the term "cell culture" refers to any
in vitro culture of cells. Included within this term are continuous cell lines (e.g., with an immortal phenotype), primary cell
cultures, transformed cell lines, finite cell lines (e.g., nontransformed cells), and any other cell population maintained
in vitro.
[0072] As used herein, the term "eukaryote" refers to
organisms distinguishable from "prokaryotes." It is intended
that the term encompass all organisms with cells that exhibit
the usual characteristics of eukaryotes, such as the presence
of a true nucleus bounded by a nuclear membrane, within
which lie the chromosomes, the presence of membranebound organelles, and other characteristics commonly
observed in eukaryotic organisms. Thus, the term includes,
but is not limited to such organisms as fungi, protozoa, and
animals (e.g., humans).
[0073] As used herein, the term "in vitro" refers to an
artificial environment and to processes or reactions that occur
within an artificial environment. In vitro environments can
consist of, but are not limited to, test tubes and cell culture.
The term "in vivo" refers to the natural environment (e.g., an
animal or a cell) and to processes or reaction that occur within
a natural environment.
[0074] The term "candidate agent" may be any substance
that potentially inhibits or enhances protein folding andor
solubility, including, but not limited to, any chemical entity,
pharmaceutical, drug, and the like (e.g., a small molecule or
compound). Candidate agents may include fragments or parts
of naturally-occurring proteins or compounds, or may be
found as active combinations of known proteins or compounds, which are otherwise inactive. It is to be understood
that candidate agents comprise both known and potential
solubility inhibiting or enhancing agents. A candidate agent
can be determined to be capable of altering target protein
solubility andor folding using the methods of the present
invention.
[0075] As used herein, the term "host cell" refers to any
cell, whether located in vitro or in vivo, that can be, or has
been, a recipient for or incorporates exogenous nucleic acid
sequences (e.g., vectors comprising fusion protein sequence),
polynucleotides andor proteins of the present invention. It is
also meant to include progeny of a single cell, and the progeny
may not necessarily be completely identical (e.g., inmorphology or in genomic or total DNA complement) to the original
parent cell due to natural, accidental, or deliberate mutations.
The cells may be eukaryotic or prokaryotic and include, but
are not limited to bacterial cells (e.g., E. coli) yeast cells,
mammalian cells, avian cells, amphibian cells, plant cells,
fish cells, and insect cells).
DETAILED DESCRIPTION OF THE INVENTION
[0076] Analysis of multiple pathways or genes in a parallel
format can be achieved using a transfected cell array, a high
throughput technique to correlate gene expression with functional cell responses, based on gene delivery from a substrate
that supports cell adhesion (See, e.g., Bengali et al., 2005,
Biotechnol Bioeng 90(3):290-302; Pannier et al., 2005, Acta
Biomaterialia 1(5):511-522; Segura and Shea, 2002, Bioconjug Chem 13(3):621-9; and Segura et al., 2003, J Control
Release 93(1):69-84). While traditional microarrays can
quantify the expression level of thousands of genes, they
cannot accurately describe the functional activity of these
genes in a cellular and physiological context (See, e.g., Pepperkok and Ellenberg, 2006, Nat Rev Mol Cell Biol7(9):690-

May 8,2008

6). Transfected cell arrays present an approach to study gene
function in the context of a living cell, allowing proteins to be
translated and folded correctly and to interact within the
environment of the cell. Additionally, a large number of genes
can potentially be screened in parallel for induction or repressionof a given function (See, e.g., Palmer and Freeman, 2005,
Pharmacogenomics 6(5):527-34). Transfected cell arrays initially offered the hope of compact, economical, and highthroughput analysis in living cells (See, e.g., Hook et al.,
2006, Trends Biotechnol24(10):471-7; Palmer and Freeman,
2005, Pharmacogenomics 6(5):527-34).
[0077] Since the original report on transfected cell arrays
(See, e.g., Ziauddin and Sabatini, 2001, Nature 411(6833):
107-lo), reverse transfection has been employed in several
high-throughput cell based microarrays to screen for gene
function or activity. Reverse transfection involves printing
mixtures of different transfection molecules (e.g., viruses
andor plasmids) with or without a carrier (e.g., gelatin) into
specific domains onto a substrate. Next, a lipid-based transfection agent can be floated over the array, and cells subsequently seeded to form a living cell microarray of locally
transfected cells in a lawn of nontransfected cells. The first
transfected cell array was used to analyze genes for phosphotyrosine activity and identified six genes; five genes that
encode known tyrosine kinase proteins and one that encodes
a protein of unknown function (See, e.g., Ziauddin and Sabatini. 2001. Nature 41 l(6833):
,
, 107-10). Transfected cell arravs
have since been applied to study signaling pathways (See,
e.g., Webb et al., 2003, J Biomol Screen 8(6):620-3; to screen
antibody fragments (See, e.g., Delehanty et al., 2004, Anal
Chem 76(24):7323-8); identify possible new lysophosphatidic acid receptors (See, e.g., Lee et al., 2006, J Biol Chem
281(33):23589-97; perform protein localization studies (See,
e.g., Hu et al., 2005, Biochem Soc Trans 33(Pt 6): 1407-8; Hu
et al., 2006, BMC Genomics 7:155), screen for proapoptotic
genes (See, e.g., Mannherz et al., 2006, Genomics 87(5):66572); Palmer et al., 2006, BMC Genomics 7(1): 145), andannotate protein function (See, e.g., Hodges et al., Mol Cell Proteomics 4(9): 1319-27). The transfected cell array has also
been adapted to high-throughput RNAi studies (See, e.g.,
Mousses et al., Genome Res 13(10):2341-7), for example, for
the analysis of spindle formation (See, e.g., Silva et al., 2004,
Proc Natl Acad Sci USA 101(17):6548-52), secretory pathways (Erfle et al., 2004, Biotechniques 37(3):454-8, 460,
462), and chromosome segregation and nuclear structure in a
time-lapse system (See, e.g., Neumannet al., 2006, Nat Methods 3(5):385-90).
[0078] Some technological improvements have enhanced
the capabilities of the arrays, but have failed to yield widespread application of transfection cell arrays. Most efforts
have focused on increasing transfection efficiency within the
array by using preformed complexes (See, e.g., Delehanty et
al., 2004, Biosens Bioelectron 20(4):773-9; Delehanty et al.,
2004, Anal Chem 76(24):7323-8; Erfle et al., 2004, Biotechniques 37(3):454-8, 460,462; Hodges et al., 2005, Mol Cell
Proteomics 4(9): 1319-27; Mousses et al., 2003, Genome Res
13(10):2341-7; Pannier et al., 2005, Acta Biomaterialia l(5):
511-522; Redmond et al., 2004, Mol Cell Proteomics 3(8):
770-9; Silva et al., 2004, Proc Natl Acad Sci USA lOl(17):
6548-52; andyoshikawa et al, 2004, J Control Release 96(2):
227-32); incorporating fibronectin (See, e.g.,Yoshikawa et al,
2004, J Control Release 96(2):227-32); atelocollagen (See,
e.g., Honma et al., 2001, Biochem Biophys Res Commun
289(5):1075-81); and recombinant proteins (See, e.g., Red-

mond et al., 2004, Mol Cell Proteomics 3(8):770-9), with
plasmid or DNA complexes, manipulating substrate hydrophobicity (See, e.g., Delehanty et al., 2004, Biosens Bioelectron 20(4):773-9), or coating cationic polymer and collagen
onto surfaces prior to transfection (See, e.g., Chang et al.,
2004, Nucleic Acids Res 32(3):e33). Micropatterning strategies have also been used to fabricate arrays, using self-assembledmonolayers to pattern DNA (See, e.g., Pannier et al.,
2005, Acta Biomaterialia 1(5):511-522; Yamauchi et al.,
2004, Biochim Biophys Acta 1672(3):138-47) or siRNA
(See, e.g., Fujimoto et al., 2006, Bioconjug Chem 17(6):
1404-10) complex immobilization on gold slides or electrodes (See, e.g., Yamauchi et al., 2004, Nucleic Acids Res
32(22):el87;Yamauchi et al., 2005, Langmuir 21(18):83607). Arrays have been formed with dendrimers (See, e.g., How
et al., 2004, Comb Chem High Throughput Screen 7(5):42330) andviral vectors (See, e.g., Bailey et al., 2006, Nat Methods 3(2): 117-22; Hobson et al., 2003, BMC Biotechnol3(1):
4; and Michiels et al., 2002, Nat Biotechnol 20(11): 1154-7)
for enhanced gene delivery, magnetic beads (Isalan et al.,
2005, Nat Methods 2(2): 113-8) or hydrogels (See, e.g.,
Peterbauer et al., 2006, Lab Chip 6(7):857-63) to localize
cells and vectors, and for alternative cell types, including
Drosophila (See, e.g., Wheeler et al., 2004, Nat Methods
1(2):127-32) and non-adherent cells (Kato et al., 2004, Biotechniques 37(3):444-8, 450, 452).
[0079] However, multiple problems remain that have precluded widespread application of transfection cell arrays.
These problem include poor transfection efficiency, spot-tospot variability, an inability to normalize data, complex and
time consuming post-transfection processing, lack of sensitivity, poor image acquisition and quantification, as well as
limitations prohibiting expansion of assessed biological endpoints.
[0080] Moreover, while there has beenmuch interest in two
dimensional transfected cell arrays (e.g., see references cited
above), three-dimensional transfected cell arrays have heretofore not been described.
[0081] Accordingly, in some embodiments, the present
invention relates to characterizing transcription within cells.
In particular, the present invention provides transfected cell
arrays (e.g., two-dimensional andor three-dimensional
arrays) and systems, kits andmethods utilizing the same (e.g.,
for transcriptional activity characterization). Compositions
and methods of the present invention find use in, among other
things, research, drug discovery and clinical (e.g., diagnostic,
preventative and therapeutic) applications.
[0082] In some embodiments, the present invention provides compositions and methods for generating transfection
cell arrays. In some embodiments, the present invention provides a transfection cell array that allows for normalization of
transfection and provides rapid and sensitive methods for
quantification of cellular responses with minimal post-transfection processing.
[0083] For example, in some embodiments, the present
invention provides a plurality (e.g., two or more) plasmid
system that provide normalization, sensitivity, and quantification (e.g., of transfection efficiency and cellular responses).
Previously utilized transfection cell arrays have been
described as suffering from spot to spot variability in transfection that compromises the ability to quantify a response
within an array (e.g., because sub-maximal responses may
indicate either a limited effect or simply inefficient or unequal
delivery). Additionally, a variance in fluorescence intensity of
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transfected cells (e.g., using GFP) has been noted between
spots of arrays (See, e.g., Hook et al., 2006, Trends Biotechno1 24(10):471-7). Accordingly, tlie present invention
addresses these shortcoming by providing, in some embodiments, compositions and methods that enable normalization
of transfection efficiency. For example, in some embodiments, a plurality plasmid (e.g., two or more plasmid) system
comprising a normalization plasmid (e.g., comprising a
reporter molecule (e.g., luciferase reporter)) that is present
within each spot (e.g., transfection zone), and a functional
plasmid (e.g., comprising areporter molecule (e.g., luciferese
reporter (e.g., that is the same or different than that within a
normalization plasmid))) that varies between spots and is
responsible for the functional endpoint of the array, is deposited in each spotitransfection zone. The present invention is
not limited by the number or type of plasmids utilized in a
system. Indeed, two, three, four or more plasmids (e.g., comprising similar or different components) may each be present
in a transfection zone or spot. In some embodiments, the
plurality of plasmids each contain the same promoter (e.g.,
TK promoter or other promoter described herein). In some
embodiments, the presence of the same promoter permits
normalization andor allows comparison between one or
more cell lines on andor in an array (e.g., a 2-dimensional or
3-dimensional array, respectively).
[0084] In some embodiments, delivery of a plurality of
plasmids results in a majority of cells expressing two or more
reporter genes (e.g., one from each plasmid). In order to
normalize data (e.g., with a second, third, fourth or more
plasmid), efficiency of delivery should be sufficient to obtain
a signal from each plasmid. The present invention addresses
obstacles encountered with poor cellular transfection of multiple plasmids in previously described transfection cell arrays
(e.g., that utilized small transfection zone andor spot sizes
(See, e.g., Palmer and Freeman, 2005, Pharmacogenomics
6(5):527-34)). For example, small spotitransfection zone size
are detrimental because each spot on the array may contain so
few cells that an insufficient number of cells are transfected
locally to be statistically informative (See, e.g., Hodges et al.,
2005, Mol Cell Proteomics 4(9):1319-27). Small spotsltransfection zones with low transfection efficiency make image
acquisition and quantification difficult and less sensitive,
leading to high false positive and false negative rates (See,
e.g., Palmer et a]., 2006, BMC Genomics 7(1):145). Thus, in
some embodiments, the present invention utilizes spot sizes
that are larger relative to traditional transfection cell arrays.
For example, in some embodiments the present invention
provides a method of generating a 2-D transfection cell array
comprising forming holes in a first material (e.g., polydimethylsiloxane (PDMS) or other material described herein) to
generate an array mold, attaching the array mold to a solid
substrate (e.g., glass, plastic, or other substrate material disclosed herein) to form a complex comprising a plurality of
wells, depositing one or more transfection molecules (e.g.,
nucleic acid (e.g., RNA, DNA, etc. (e.g., within a plasmid or
virus)) into the plurality of wells under conditions such that
the transfection molecules are immobilized on the solid substrate (e.g., in the hole (e.g., spot or transfection zone)) and
removing the array mold from the solid substrate to generate
an array (e.g., of one or more transfection molecules) on the
substrate. In some embodiments, the transfection molecules
colnprise a nucleic acid vector (e.g., plasmids). In some
embodiments, the plasmid comprises a reporter gene. In some
embodiments, the plasmid comprises a promoter region (e.g.,

configured to bind transcription factors). In some embodiments, the solid substrate is polystyrene. In some embodiments, tlie spot or transfection zone corriprises a second vector (e.g., plasmid). In some embodiments, a second plasmid
comprises a nucleic acid sequence comprising a reporter gene
and a promoter region (e.g., that permits transcription efficiency to be normalized (e.g., between spotsltransfections
zones present in the array)). Preferred sizes of the spots1
transfection zones are described herein. In some embodiments, a transfection cell array of the present invention (e.g.,
fabricated by methods disclosed herein (e.g., to produce
large, useful spotitransfection zone sizes) is compatible with
viral delivery of transfection molecules (See, e.g., Bailey et
al., 2006, Nat Methods 3(2):117-22; Hobson et al., 2003,
BMC Biotechnol3(1):4; Michiels et al., 2002, Nat Biotechno1 20(11):1154-7). In some embodiments, a transfection cell
array of the present invention (e.g., fabricated by methods
disclosed herein (e.g., to produce large, useful spotitransfection zone sizes) is compatible with plasmid delivery of transfection molecules. In some embodiments, a transfection cell
array of the present invention is compatible with delivery of
transfection molecules andor other agents (e.g., candidate
agents, drugs, oligonucleotides, etc.) via non-viral mediated
and non-transfection mediated delivery (e.g., via receptor
mediated endocytosis, phagocytosis, diffusion, etc.).
[0085] In some embodiments, the present invention provides a method of screening transcriptional activity within
cells comprising exposing an array (e.g., of transfection zones
on a solid substrate comprising transfection molecules (e.g.,
wherein the transfection molecules comprise a first nucleic
acid vector comprising a reporter gene and a promoter region
configured to bind transcription factors and a second nucleic
acid vector comprising a promoter configured for standardization of transfection efficiency)), wherein the array is generated by forming holes in a first material (e.g., polydimethylsiloxane (PDMS) or other material described herein) to
generate an array mold, attaching the array mold to a solid
substrate (e.g., glass, plastic, or other substrate material disclosed herein) to form a complex comprising a plurality of
wells, depositing one or more transfection molecules (e.g.,
nucleic acid (e.g., RNA, DNA, etc. (e.g., within a plasmid or
virus)) into the plurality of wells under conditions such that
the transfection molecules are immobilized on the solid substrate (e.g., in the hole (e.g., spot or transfection zone)) and
removing the array mold from the solid substrate to generate
an array (e.g., of one or more transfection molecules) on the
substrate), to cells under conditions such that transcriptional
activity within the cells is altered, and detecting the transcriptional activity within tlie cells. In some embodiments, detecting transcriptional activity within the cells comprises detecting expression of a reporter gene.
[0086] In some embodiments, bioluminescence imaging
(See, e.g., Rutter et al., 1998, Chem Biol 5(11):R285-90) is
used with a transfection cell array (e.g., 2-dimensional (2-D)
andor 3-dimensional (3-D) array) described herein to quantify the response of transfection molecules (e.g., two or more
vectors canying transfection molecules) within the array
(e.g., with minimal post-transfection processing and with
high sensitivity). Previously utilized transfection cell arrays
suffer from endpoint analysis that may require tagging or
staining (See, e.g., Hook et al., 2006, Trends Biotechnol
24(10):471-7) to report gene fwlction, which can require
extensive post-transfection processing, such as fixation and
immunostaining (See, e.g., Lee et al., 2006, J Biol Chem
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281(33):23589-97; Wheeler et al., 2005, Nat Methods l(2):
127-32). In contrast, a transfection cell array fabricated and
usedaccording to compositions andmethods disclosed herein
permit rapid endpoint quantification (e.g., in each spotltransfection zone (e.g., via sequential addition of substrates)). For
example, in some embodiments, two or more transfection
molecules (e.g., normalization andor functional plasmid
vectors) contain renilla andor firefly luciferase reporters
(e.g., the substrates of which can be added directly to culture
media followed by imaging of the array (e.g., of cells present
in the array (e.g., cells that have been transfected using compositions and methods of the present invention))). Luciferase
reporters are more sensitive than GFP, without the issues of
autofluorescence and background signals (See, e.g., Rutter et
al., 1998, Chem Biol 5(11):R285-90). Luciferase is more
quantitative and allows for small differences in expression to
be determined, which, in some embodiments, permits an
array of the present invention to determine a dose response to
an external stimulus. In some embodiments, the short halflife of luciferase permits for real-time imaging (e.g., to identify andor characterize dynamics of gene activity (See, e.g.,
Rutter et al., 1998, Chem Biol 5(11):R285-90). In some
embodiments, the present invention utilizes imaging systems
that use automated microscopy and image processing (See,
e.g., Pepperkok and Ellenberg, 2006, Nat Rev Mol Cell Biol
7(9):690-6; Wheeler et al, 2005, Nat Methods 1(2):127-32)
(e.g., that allow for detection of changes in cellular morphology and cellular expression (e.g., nucleic acid, protein, etc.)
level data (e.g., that is not possible with bioluminescence
imaging)). The present invention is not limited by the endpoint data analysis methods utilized. Indeed, avariety of other
methods mav find use with the comvositions and methods of
the present invention including those described herein.
[0087] Compositions and methods of the present invention
were utilized to quantify the activity of estrogen rector-alpha
(ERu) in breast cancer cells with an estrogen-response-element (ERE)-regulated promoter reporter system (e.g., as an
example of an inducible vector (e.g., plasmid) system (e.g., in
a cancer model)). ERu, a member of the nuclear receptor
superfamily of transcription factors, activates transcription
through binding of its ligand, 17-P-estradiol (E,). Expression
of ERu is used clinically as a biomarker to determine treatment for breast cancer patients (See, e.g., Ariazi et al., 2006,
Curr Top Med Chem 6(3): 181-202; Pearce and Jordan, 2004,
Crit. Rev Oncol Hematol 50(1):3-22). However, simple
expression of transcription factors like ERu does not necessarily reflect pathway activation, as transcription factor activity is regulatedthroughdiversemechanisms (See, e.g., Levine
and Tijan, 2003, Nature 424(6945):147-51), including heteromeric complexes, ubiquitination, methylation, acetylation, and post-translational modifications such as phosphorylation. However, in some embodiments, compositions and
methods of the present invention allow for the determination
of transcription factor activity. For example, the present
invention provides the ability to characterize the induction of
activity of ERu by E,. Induction in a transfection cell array of
the present invention mimicked results obtained through traditional luciferase assay methods, with E, inducing luciferase
expression 10-fold over fulvestrant or vehicle controls (See,
e.g., Examples 1-5). An array of the present invention is also
able to characterize activity in response to a range of dosages
(e.g., the varying ER activity in response to a range of E,

dosages was detected (See, e.g. Examples 4-5)) demonstrating the sensitivity of the compositions andmethods disclosed
herein.
[0088] In some embodiments, the present invention provides a 3-D array (e.g., transfection cell array). In some
embodiments, the 3-D array is generated by spotting a substrate with a biopolymer solution containing cells (e.g., from
a cell culture line, freshly harvested cells, cloned cells, transformed cells, etc.) and transfection molecules (e.g., vectors
containing nucleic acid (e.g., DNA, RNA, cDNA, tRNA,
siRNA) of interest) (See, e.g., Example 6). Thus, in some
embodiments, the present invention provides a composition
comprising a 3-D transfection cell array comprising an array
of spatially controllable immobilized gels, wherein the gels
comprise a crosslinkable biopolymer solution comprising
cells exposed to transfection molecules (e.g., presented by a
transfectionrea~ent).
Thus. in some embodiments. in contrast
u
,
to substrate-mediated delivery of a transfection molecule
(e.g., delivered via a 2-D transfected cell array (e.g., with a
transfection molecule immobilized to a surface)), the present
invention provides for polymeric-mediated delivery of transfection molecules to cells within a 3-dimensional transfection
cell array (e.g., via distribution (e.g., homogenous distribution) of transfection molecules and cells within a polymer
(e.g., biopolymer (e.g., acrylated poly(ethy1ene glycol)
(PEG-Acryl)hydrogels, collagen gels, alginate gels, or other
suitable biomaterial disclosed herein)).
[0089] In some embodiments, the biopolymer is crosslinked (e.g., forming an array of spatially controlled, immobilized gels). In some embodiments, the transcriptional activity of the cells (e.g., within spatially controlled, immobilized
gels) is determined. The present invention is not limited by
the method of characterizing the transcriptional activity of the
cells. Indeed, a variety of methods are contemplated to be
useful for characterizing such activity including, but not limited to those described herein. In some embodiments, a vector
(e.g., plasmid) encoding a luciferase reporter gene driven by
a regulated promoter is utilized. In some embodiments,
expression of nucleic acid expression is determinedcharacterized. In some embodiments, detection of protein expression is determinedcharacterized. A vast of amount of information can be accumulated via such characterization. For
example, the present invention provides a method for generating andor characterizing information regarding signaling
pathways and the production of genes relevant to cancer
progression. Indeed, many other types of information are
contemplated to be collected as described herein.
[0090] In some embodiments, transcriptional activation as
well as transfection efficiency can be quantified (e.g., by
analyzing the level of reporter (e.g., luciferase) expression
(e.g., through automated andor manual visual imaging of
light production by the reporter (e.g., luciferase) upon the
addition of its substrate luciferin)). In some embodiments,
transfection efficiency is determined via normalization with a
separate vector (e.g., plasmid) containing a minimal promoter
driving a second reporter gene (e.g., a second luciferase or
other reporter gene). In some embodiments, a 3-D transfection cell array provides an in vivo like cellular environment to
evaluate cell performance. In some embodiments, the 3-D
cellular array is utilized to evaluate (e.g., characterize andor
detect) cancer cell formation into cell structures. It is contemplated that data generated utilizing compositions and methods of the present invention will find use to assist in characterizing tumor stage and pathologic grade (e.g., physician's
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assessment of grade andor pathology). However, the present
invention is not so limited. For example, as described herein,
information generated utilizing compositions and methods of
the present invention also find use in molecular staging of
disease, diagnostics and prognostics for disease and treatment, and as research tools (e.g., to analyze the activity of
cellular signaling pathways (e.g., in specific cell populations
andor under specific environmental conditions), to characterize cellular matrix design (e.g., how matrix design correlates with cellular response and cellular signaling pathways),
and for characterizing tissue engineering (e.g., by providing a
method for screening changes incell activity andmorphology
(e.g., as function of gel rigidity and composition (e.g., when
various extracellular matrices are also incorporated)))). In
some embodiments, 3-D transfection cell arrays and methods
of using the same described herein provide information
regarding effects on cell morphology and transcriptional activation as a function of gel elasticity, crosslink density, mesh
size andor composition (e.g., comprising extracellularmatrices).
[0091] In some embodiments, the present invention provides compositions and methods (e.g., using 2-D andor 3-D
transfection cell arrays described herein) for high throughput
analysis of gene function in cells. For example, in some
embodiments, compositions and methods of the present
invention provide the ability to screen large sets of nucleic
acid constructs for those encoding desired products or for
causing cellular phenotypes of interest. In some embodiments, cells transfected using a 2-D or 3-D cell array
described herein can be screened for the ability of a transfection molecule (e.g., nucleic acid) andor other agent (e.g.,
candidate agent) to confer a particular phenotype on the cells,
and, by reference to the position of the cell(s) on the array, the
identity of the transfection molecule (e.g., nucleic acid) or
other agent can be determined.
[0092] Accordingly, the present invention is related to a
method, referred to as a reverse transfection method, in which
a defined transfection molecule (e.g., nucleic acid (e.g., a
nucleic acid of known sequence or source)), is introduced into
cells in defined areas (e.g., within a "lawn" of eukaryotic
cells) in a 2-D array, or within a 3-D spatially controllable,
immobilized gel comprising a crosslinkable biolpolymer
cells and transfection molecules, in which the transfection
molecules will be expressed or may have an effect on or
interact with a cellular component or function. The present
invention is not limited by the type of transfection molecule
utilized. For example, any suitable nucleic acid such as an
oligonucleotide, DNA and RNA can be used as a transfection
molecule in the methods of the present invention. Moreover,
the nucleic acid may be present in a plasmid or vector for
expression, or not. It should be understood that any suitable
nucleic acid can be utilized in the compositions and methods
of the present invention.
[0093] In some embodiments, the present invention provides a method in which a transfection molecule (e.g., DNA
(e.g., DNA of known sequence or source)) is introduced into
cells in defined areas of a "lawn" of cells (e.g., eukaryotic
cells), in which it will be expressed orwill itselfhave an effect
on or interact with a cellular component or function. In some
embodiments, a mixture comprising transfection molecules
(e.g., nucleic acid (e.g., DNA (e.g., cDNA)) of interest (e.g.,
incorporated into an expression plasmid or vector)) and a
carrier protein (e.g., a lipid based or gelatin based carrier (See,
e.g. U.S. Patent Application Publication No. 20030228601,

hereby incorporated by reference in its entirety)) is deposited
into a plurality of wells in an array mold (e.g., formed by
generating holes in a first material (e.g., polydimethylsiloxane (PDMS) or other material described herein) to generate
an array mold, attaching the array mold to a solid substrate
(e.g., glass, plastic, or other substrate material disclosed
herein) to form a complex comprising a plurality of wells)),
under conditions such that the transfection molecules are
immobilized on the solid substrate (e.g., in the hole (e.g., spot
or transfection zone)), wherein the array mold is removed
from the solid substrate to generate an array (e.g., of one or
more transfection molecules) on the substrate. In some
embodiments, a mixture comprising spatially controllable,
immobilized gels, wherein the gels comprise a crosslinkable
polymer, cells and transfection molecules are arrayed on a
substrate to form a plurality of transfection zones or spots.
[0094] The transfection molecules andor carrier protein(s)
can be deposited in as many discrete locations (e.g., spots or
transfection zones created by making holes in a first material
(e.g., for 2-D arrays), or by controlling the spatial location of
immobilized gels (e.g., for 3-D arrays)) as desired. Thus, the
present invention is able to produce a surface bearing a plurality of transfection molecules in defined, distinct locations
wherein the identity of the transfection molecule in each of
the transfection zones/spots is knowddefined.
[0095] In some embodiments, eukaryotic cells, such as
mammalian cells (e.g., human, monkey, canine, feline,
bovine, or murine cells), bacterial, insect, or plant cells, are
plated (placed) onto the surface bearing the transfection molecules (e.g., vector DNA (e.g., for 2-D arrays)) or are mixed
with transfection molecules and a crosslinkable linker (e.g.,
for 3-D arrays) in sufficient density and under appropriate
conditions for introductiodentry of the transfection molecules into the eukaryotic cells (e.g., host cells) and expression of the DNA or its interaction with cellular components
monitored andor characterized.
[0096] In some embodiments, the concentration andor
amount of transfection molecules (e.g., placed in a hole
formed in a first material (e.g., PDMS) or mixed with a
crosslinkable volvmer and cells can be determined emvirically for each use. However, it is contemplated that when the
transfection molecule is nucleic acid, the concentration will
generally be in the range of from about 0.001 pglpl to about
0.2 pg/pl and, in some embodiments, is from about 0.005
pg/pl to about 0.10 pglpl. Alternatively, the concentration of
DNA present in the mixture can be from about 0.01 pglpl to
about 0.5 pg/pl, from about 0.007 pg/pl to about 0.021 pg/pl
and from about 0.01 pglpl to about 0.3 pg/pl.
[0097] In some embodiments, the amount of nucleic acid
utilized is determined per surface area. For example, in some
embodiments, the amount of nucleic acid used will generally
be in the range of from about 0.001 pg/cm2to about 5 pg/cm2
and, in some embodiments, is from about 0.05 pg/cm2 to
about 0.5 pg/cm2.Alternatively, the amount of DNA present
can be from about 0.01 pg/cm2 to about 1.0 pg/cm2, from
about 9.03 pg/cm2to about 0.75 pg/cm2 and from about 0.1
pg/cm to about 2.5 pg/cm2.
[0098] In some embodiments, when a carrier molecule is
utilized with transfectionmolecules for addition to a plurality
of wells formed by punching holes in a first material (e.g.,
PDMS), the concentration of the carrier molecule (e.g., gelatin or another carrier macromolecule) can be determined
empirically for each use, but will generally be in the range of
0.01% to 0.5% and, in specific embodiments, is from about

.,

May 8,2008

0.05% to about 0.5%, from about 0.05% to about 0.2% or
from about 0.1% to about 0.2%.
[0099] In some embodiments, when cells are mixed with
transfection molecules and a crosslinkable biopolymer (alginate andor alginatelcollagen), the concentration of the
crosslinkable biopolymer can be determined empirically for
each use, but will generally be in the range of 1% to 5%
alginate, and, in specific embodiments, is from about 1% to
about 2% alginate, from about 1.4% to about 1.6% alginate or
from about 0.1% to about 5% alginate, although higher and
lower percentages are contemplated. Similarly, the concentration of collagen will generally be in the range of 0.1% to
3% alginate, and, in specific embodiments, is from about
0.1% to about 0.3% alginate, from about 0.1% to about 0.2%
alginate or from about 0.05% to about 5% alginate, although
higher and lower percentages are contemplated.
[0100] In some embodiments, a charge neutralizing reagent
(e.g., polyethyleimine (PEI)) is added to the solution comprising crosslinkable biopolymer and cells and transfection
molecules. In some embodiments, the charge neutralizing
reagent is added such that the nitrogen to phosphate (N:P)
ratio is achieved to attain an optimal charge balance for transfection (e.g., optimal transfection). In some embodiments,
the N:P ration is between around 15-35, from about 20-30, or
from about 22-27, although higher and lower charge ratios
may be used (e.g., depending on the type of cell and types of
transfection molecules utilized). In some embodiments, a
transfection efficiencyof greater than about 50%, greater than
60%, greater than 70%, greater than SO%, or greater than 90%
is achieved, although higher and lower transfection efficiencies may be attained.
[0101] In some embodiments, if the transfection molecule
(e.g., nucleic acid (e.g., DNA, RNA, cDNA, etc.)) used is
present in a vector, the vector can be of any type, such as a
plasmid or viral-based vector, into which a nucleic acid of
interest (e.g., DNA to be expressed in reverse transfected
cells) can be introduced and expressed (e.g., after reverse
transfection) in recipient cells. For example, a CMV-driven
expression vector can be used. Commercially available plasmid-based vectors, such as pEGFP (CLONTECH) or
pcDNA3 (INVITROGEN), or viral-based vectors can be used
(See, e.g., U.S. Patent Application Publication Nos.
20030228601 and 20060257858, each of which is hereby
incorporated by reference in its entirety for all purposes).
[0102] In some embodiments, to generate a transfection
cell arrav. cells are either vlated over an arrav formed on a
solid surface (e.g., for a 2-D array) or are mixed with transfection molecules and a crosslinkable biopolymer prior to
immobilizing in a spacially definedarea on substrate (e.g., for
a 3-D array). In some embodiments, actively growing cells
are4 generally used and are plated, preferably in the range of
10 -lo7 cells/cm2 (although higher and lower concentrations
are contemplated (e.g., depending upon the cell type) on top
of the substrate surface containing the affixed transfection
molecules (e.g., nucleic acids (e.g., in media such as Dulbecco's Modified Eagles Medium (DMEM) containing 10%
heat-inactivated fetal serum (IFS) with L-glutamine and penicillidstreptomycin (pedstrep) or other media)); or for 3-D
gels, are mixed with transfection molecules and a crosslinkable biopolymer in the range of lo4-lo6 cells/mL, although
more or less cells can also be used (e.g., based upon the type
of cells to be transfected).
[0103] The transfection cell arrays (e.g., 2-D andor 3-D
arrays comprising cells and transfection molecules) are main2 ,

tained under conditions appropriate for growth of the cells
and entry of DNA, such as an entry of an expression vector
containing the DNA, into cells. For example, in some
embodiments, one to two cell cycles are sufficient for reverse
transfection to occur, but this can vary depending upon the
cell type and conditions used and the appropriate length of
time for a specific combination can be determined empirically. After sufficient time has elapsed, cells can be assessed
for reverse transfection (e.g., entry of transfection molecules
(e.g., nucleic acid (e.g., DNA)) into cells) and expression of
the encoded product or effect of the introduced DNA on
reverse-transfected cells, using known methods. This can be
done, for example, by detecting immunofluorescence or
enzyme immunocytochemistry, autoradiography, in situ
hybridization, or other means of detecting expression of the
DNA or an effect of the encoded product or of the DNA itself
on the cells into which it is introduced.
[0104] In some embodiments, detection of transfection
(e.g., alteration of transcription within transfected cells) utilizes detection of a reporter system (e.g., renilla andor firefly
luciferasereporters (e.g., the substrates ofwhichcan be added
directly to culture media followed by imaging of the array
(e.g., of cells present in the array (e.g., cells that have been
transfected using compositions and methods of the present
invention))).
[0105] In some embodiments, immunofluorescence can
used to detect expression of an encoded protein (e.g., an
antibody that binds a protein and is fluorescently labeled can
used (e.g., added to an array under conditions suitable for
binding of the antibody to the protein) and the location (e.g.,
transfection zone or spot) of the protein identified by detecting fluorescence). In some embodiments, the presence of
fluorescence indicates that reverse transfection has occurred
and the encoded protein has been expressed in the defined
location(s) which show fluorescence. The presence of a signal, detected by the method used, on the slides indicates that
reverse transfection of the DNA into cells and expression of
the encodedproduct or an effect of the DNA in recipient cells
has occurred in the defined location(s) at which the signal is
detected. As described above, the identity of the DNA present
at each of the defined locations is known; thus, when expression occurs, the identity of the expressed protein is may also
known.
[0106] In some embodiments, the present invention provides a method for expressing specific, identified nucleic
acids (e.g., cDNAs or genomic DNAs), in defined locations or
areas of a surface (e.g., transfection zones or spots) onto
which the same or different nucleic acids (e.g., variants,
mutants, etc.) have been attached. Thus, because each area of
the surface can be coveredspotted with nucleic acid of a
known composition, this permits identification of the
expressed protein. In addition, the present method is useful to
identify DNAs whose expression alters (enhances or inhibits)
a pathway, such as a signaling pathway in a cell or another
property of a cell, such as its morphology or pattern of gene
expression. In some embodiments, compositions and methods of the present invention are useful, for example, as a
high-throughput screening method, such as in a microarray
format. Thus, compositions and methods described herein
can be used for identifying nucleic acids whose expression
change the post-translational status andor subcellular location of a protein of interest or the effect of a test compound or
agent on the cell (e.g., cellular activity post exposure to a test
agent or compound (e.g., a small molecule, drug, hormone,

May 8,2008

siRNAetc.)). Thus, in some embodiments, compositions and
methods of the present invention can be utilized to characterize cellular activity (e.g., transcriptional activity) post exposure of cells to a test agent, by measuring transcriptional
activity (e.g., of a reporter system) within the cell.
[0107] In some embodiments, the present invention provides methods of making arrays of the present invention. The
methods comprises The method comprises affixing DNAs or
reverse transfected cells onto a surface by the steps described.
herein for the gelatin-DNA embodiment or the lipid-DNA
embodiment.
[0108] In some embodiments, the present invention relates
to a method of introducing specific, known transfection molecules (e.g., nucleic acids (e.g., DNA)) at specific, discrete,
defined locations (e.g., transfection zones or spots) on a substrate surface by lneans of a reverse transfection method. The
size of the transfection zonesispots, the quantity (density) of
the transfection zonesispots and the configuration of the
transfection zoneispots can be adjusted depending upon a
variety of factors (e.g., the type of cells used, the conditions
used to transfect, etc.). For example, in some embodiments,
the transfection zonesispots can be from about 0.1 to about 10
mm in diameter, from about 0.5 to about 10 mm in diameter,
from about 1 to about 5 mm in diameter, from about 2 to about
4 rnm in diameter, or from about 2.3 to about 2.5 mm in
diameter, although larger and smaller diameters are contemplated. In some embodiments, each transfection zoneispot is
from about 0.1 to about 0.9 mm away from another transfection zoneispot.
[0109] In some embodiments, the present invention provides identification andor detection of cells into which transfection molecules have been transfected (e.g., reverse transfected). In one embodiment, transfection molecules (e.g.,
DNA) introduced into cells are expressed in the cells, either
by an expression vector containing the molecules (e.g., DNA)
or as a result of integration of molecules (e.g., DNA) into host
cell DNA, from which it is expressed. In some embodiments,
nucleic acids (e.g., RNA (e.g., siRNA) or DNA) are introduced to cells (e.g., are not transfectedly expressed in the
cells), and are able to alter cellular components and/or function (e.g., that can be detected using the compositions and
methods of the present invention (e.g., reporter constructs
transfected into cells). For example, small inhibitory RNAs or
other antisense molecules can be introduced into cells to alter
cell function. In some embodiments, a nucleic acid can be
transfected into the cell, wherein the nucleic acid inhibits
expression of other nucleic acids in the cell. For example, a
DNA fragment which is anti-sense to an mRNA (e.g., encoding a receptor for a drug) can be introduced into cells via
reverse transfection. The anti-sense DNA may decrease the
expression of mRNA (e.g., of the drug receptor protein (e.g.,
causing a decrease in drug binding to cells containing the
anti-sense DNA)).
[0110] In some embodiments, the present invention provides detection of effects on recipient cells (cells containing
transfection molecules introduced using an array of the
present invention) that can be carried out by a variety of
known techniques, such as immunofluorescence (e.g., of a
reporter construct (e.g., a luciferase reporter) or of a protein
(e.g., in which a fluorescentIy IabeIed antibody that binds a
protein of interest (e.g., a protein thought to be encoded by a
reverse transfected DNA or a protein whose expression or
function is altered through the action of the reverse transfected DNA)).

[Olll] In some embodiments, compositions and methods
of the present invention are utilized to identify nucleic acids
(e.g., DNAs) of interest (nucleic acids that are expressed in
recipient cells or act upon or interact with recipient cell constituents or function (e.g., nucleic acids that encode a protein
whose function is desired because of characteristics its
expression gives cells in which it is expressed)). In some
embodiments, an array of the present invention can be utilized
as a protein or cell array (e.g., a protein microarray or a cell
microarray).
[0112] The present invention is not limited by the type of
nucleic acid utilized (e.g., as a transfection molecule (e.g.,
introduced into cells for expression)) in a 2-D andor 3-D
transfection array described herein. The nucleic acid molecules used in the transfection arrays of the present invention
can be, for example, DNA, RNA or modified or hybrid forms
thereof. The nucleic acids may be from any of a variety of
sources, such as nucleic acid isolated from cells, or that which
is recombinantly produced or chemically synthesized.
[0113] In some embodiments, the nucleic acids include
coding sequence from cDNAs or genomic DNA. In addition
to native sequences, the coding sequences can include those
which have been mutated relative to the native sequence (e.g.,
a coding sequence that differs from a naturally occurring
sequence by deletion, substitution or addition of at least one
residue). It can correspond to full length or partial sequences,
can be antisense in orientation, or can represent a non-coding
sequence.
[0114] In some embodiments, all or a portion of the nucleic
acid sequence can be synthesized chemically. Thus, random
and semi-random sequence can be introduced into the nucleic
acid sequences, as well as modified forms of nucleotides and
nucleotide linkages, such as the use of modified backbones,
methylated nucleotides and the like.
[0115] As described herein, the nucleic acid sequences can
be present as part of a larger vector, such as an expression
vector (e.g., a plasmid or viral-based vector), but it need not
be. The nucleic acid of the array can be introduced into cells
in such a manner that at least the a portion of the nucleic acid
sequence (e.g., a portion that varies from transfection zone1
spot to transfection zoneispot) becomes integrated into cellular genomic DNA and is expressed, or remains extrachromosomal (e.g., is maintained episomally).
[0116] The nucleic acid sequences (e.g., utilized in transfection cell arrays of the present invention) can be linear or
circular, double stranded or single stranded, and can be of any
size. In some embodiments (e.g., when expression vectors are
used) nucleic acid sequences expressed in cells (e.g., resulting from transfection of cells with a vector comprising the
nucleic acid sequence) is from about 200 nucleotides (nt) to
about 10 kilobases (kb) in size, in some embodiments, from
about 200 nt to about 5 kb, and in some embodiments, from
about 200 nt to 2 kb, although shorter or longer sequences
may be expressed. In some embodiments, the nucleic acid
sequence transfected into cells (e.g., including vector
sequence) is from about 1 kb to about 15 kb, although larger
and smaller constructs are also contemplated herein.
[0117] In some embodiments, a transfectioncell array (e.g.,
2-D or 3-D array) of the present invention comprises a variegated library of expression vectors.
[0118] The present invention is not limited by the type of
vector utilized (e.g., to introduce a transfection molecule
(e.g., into cells for expression)) in a 2-D andor 3-D transfection array described herein. In general, it will be desirable that
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the vector be capable of replication in the host cell. It may be
a DNA (e.g., plasmid DNA) which is integrated into the host
genome, and thereafter is replicated as a part of the chromosomal DNA, or it may be DNA which replicates autonomously (e.g., an episomal plasmid). In the latter case, the
vector will include an origin of replication which is functional
in the host. In the case of an integrating vector, the vector may
include sequences that facilitate integration (e.g., sequences
homologous to host sequences, or encoding integrases). The
use of retroviral long terminal repeats (LTR) or adenoviral
inverted terminal repeats (ITR) in the construct of a transfection array can, for example, facilitate the chromosomal integration of the construct.
[0119] Cloning and expression vectors for use with bacterial, fungal, yeast, and mammalian cellular hosts are known in
the art, and are described in, for example, Powels et al. (Cloning Vectors: A Laboratory Manual, Elsevier, N.Y., 1985).
Such vectors may be readily adapted for use in the present
invention. The expression vectors may comprise non-transcribed elements such as an origin of replication, a suitable
promoter and enhancer linked to the gene to be expressed, and
other 5' or 3' flanking nontranscribed sequences, and 5' or 3'
nontranslated sequences (e.g., ribosome binding sites, a polyadenylation site, splice donor and acceptor sites, and transcriptional termination sequences).
[0120] In some embodiments, expression vectors contain
bothprokaryotic sequences (e.g., to facilitate the propagation
of the vector in bacteria (e.g., in an amplification step after
recovery from the array)), andor one or more eukaryotic
transcription units for expressing the target sequence in
eukaryotic host cells. The pcDNAIIamp, pcDNAIIneo, pRc1
CMV, pSV2gpt, pSV2ne0, pSV2-dhfr, pTk2, pRSVneo,
pMSG, pSVT7, PKO-neo and pHyg derived vectors are
examples of mammalian expression vectors that can be
readily adapted for use in the compositions and methods of
the present invention. Some of these vectors are modified
with sequences from bacterial plasmids, such as pBR322, to
facilitate replication and drug resistance selection in both
prokaryotic and eukaryotic cells. Alternatively, derivatives of
viruses, such as the bovine papillomavirus (BPV-I), or
Epstein-Barr virus (pHEBo, PREP-derived and p205) and the
like, can also be used. The various methods employed in the
preparation of the plasmids are well known in the art. For
other suitable expression systems for both prokaryotic and
eukaryotic cells, as well as general recombinant procedures,
see, e.g., Molecular Cloning A Laboratory Manual, 2nd Ed.,
ed. by Sambrook, Fritsch and Maniatis (Cold Spring Harbor
Laboratory Press: 1989) Chapters 16 and 17.
[0121] In some embodiments, vectors contain regulatory
elements that can be linked to the target sequence for transfection of mammalian cells. Examples of such vectors
include, but are not limited to, cytomegalovirus (CMV) promoter-based vectors such as pcDNAl (INVITROGEN, San
Diego, Calif.), MMTV promoter-based vectors such as
pMAMNeo (CLONTECH, Palo Alto, Calif.) and pMSG
(PHARMACIA, Piscataway, N.J.), and SV40 promoterbasedvectors such as pSVO (CLONTECH, Palo Alto, Calif.).
[0122] A number of vectors exist for the expression of
recombinant proteins in yeast (e.g., where yeast are used as a
host cell in an array). Examples include, but are not limited to,
YEP24,YIP5,YEP51,YEP52, pYES2, andYRP17, andother
cloning and expression vehicles useful in the introduction of
genetic constructs into S. cerevisiae (See, e.g., Broach et al.
(1983) in Experimental Manipulation of Gene Expression,

ed. M. Inouye Academic Press, p. 83, incorporated by reference herein). These vectors can replicate in E. coli due the
presence of the pBR322 ori, and in S. cerevisiae due to the
replication determinant of the yeast 2 micron plasmid. Moreover, if yeast are used as a host cell, it will be understood that
the expression of a gene in a yeast cell requires a promoter
which is functional in veast. Suitable vromoters include. but
are not limited to, the promoters for metallothionein, 3-phosphoglycerate kinase (See, e.g., Hitzeman et al., J. Biol. Chem.
255,2073 (1980) or other glycolytic enzymes (See, e.g., Hess
et al., J. Adv. Enzyme Req. 7, 149 (1968); and Holland et al.
Biochemistry 17, 4900 (1978)), such as enolase, glyceraldehyde-3-phosphate dehydrogenase, hexokinase, pyruvate
decarboxylase, phospho-fructokinase, glucose-6-phosphate
isomerase, 3-phosphoglycerate mutase, pyruvate kinase, triosephosphate isomerase, phospho-glucose isomerase, and
glucokinase.
[0123] The present invention is not limited by the source of
transfection moleclue (e.g., introduced into cells for expression)) utilized in a 2-D andor 3-D transfection array
described herein. For example, in some instances, it may be
desirable to derive the host cell using insect cells. In such
embodiments, the transfection array can be derived from, for
example, a baculovirus expression system. Examples of such
baculovirus expression systems include, but are not limited
to, pVL-derived vectors (e.g., pVL1392, pVL1393 and
pVL941), pAcUW-derived vectors (e.g., pAcUWI), and
pBlueBac-derived vectors (e.g., beta-galactosidase containing pBlueBac 111).
[0124] In some embodiments, where the source of target
sequence for the array are naturally occurring, sequences can
be isolated from any cell or collection of cells. For example,
the target sequences can be isolated from the cells of either
adult tissue or organs or embryonic tissue or organs at any
given developmental stage (e.g., including, but not limited to,
oocyte, blastocyte, etc.). The cells can be derived from
healthy tissue or diseased tissue. In the case of a solid organ,
cells can be obtained by biopsy or other mechanical means.
For blood, lymph and other bodily fluids, cells can be isolated
from the fluid component (e.g., by filtration, affinity purification, centrifugation or any other technique known in the art).
The cells can be isolated to include a specific subset of phenotypes of cells from a given tissue, or can include or can be
derived to include all or a substantial portion of cells representative of the tissue. For example, cells can be derived from
an organ where the cells are particularly of epithelial, mesenchymal or endothelial origin. Subsets of cells can be isolated, for example, by use of cell surface markers or careful
sectioning of a tissue.
[0125] In some embodiments, cells can be harvested from
neoplastic or cancerous tissue. For example, cells may be
cultured from any type of tumor or cancerous tissue (e.g.,
identified via pathologic means).
[0126] In some embodiments, nucleic acid sequences (e.g.,
transfected into host cells) are cDNA sequences (e.g., derived
from mRNA isolated from a cell or cells of interest (e.g.,
cancer cell or normal cell) or that are chemically synthesized). There are a variety of methods known in the art for
isolating RNA from a cellular source. For example, isolation
of total cellular RNA using guanidine isothiocyanate (described, e.g., in U.S. Pat. No. 4,843,155) used in conjunction
with, for example, oligo-dT strepavidin beads, is an example
of one means of isolating mRNA. The RNA, as desirable, can
be converted to cDNA using reverse transcriptase.
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[0127] A wide range of techniques for isolating genomic
DNA exist that are amenable for use in a varietv of embodiments of the present invention. In some embodiments, only a
portion of the total genomic DNA is isolated (e.g., on the basis
of the chemical andor physical state in which it is present
(e.g., in a collection of cells)). For example, transcriptionally
active andor potentially active genes can be isolated (e.g.,
away from inactive sequences (e.g., using Dnase I digestion).
[0128] The present invention is not limited by the type of
nucleic acid utilized (e.g., as a transfection molecule (e.g.,
that is introduced into cells for expression)) in a 2-D andor
3-D transfection array described herein. In some embodiments, libraries of nucleic acid molecules are utilized in a
transfection array. In some embodiments, an array may comprise a library of related, mutated sequences, such as a library
of mutants of a particular protein, or libraries of potential
promoter sequences, etc. A variety of forms of mutagenesis
exist that are well known in the art that can be utilized to
generate a combinatorial library. For example, homologs of a
protein of interest can be generated and isolated from a library
by screening using, for example, alanine scanning mutagenesis and the like (See, e.g., Ruf et al. (1994) Biochemistry
33:15 65-1572; Wang et al. (1994) J. Biol. Chem. 269:30953099; Balint et al. (1993) Gene 137:109-118; Grodberg et al.
(1993) Eur. J. Biochem. 218:597-601; Nagashima et al.
(1993) J. Biol. Chem. 268:2888-2892; Lowinan et al. (1991)
Biochemistry 30:10832-10838; and Cunningham et al.
(1989) Science 244: 1081-1085), by linker scanning
mutagenesis (See, e.g., Gustinet al. (1993)Virology 193:653660; Brown et al. (1992) Mol. Cell. Biol. 12:2644-2652;
McKnight et al. (1982) Science 232:316); by saturation
mutagenesis (See, e.g., Meyers et al. (1986) Science 232:
613); by PCR mutagenesis (See, e.g., Leung et al. (1989)
Method Cell Mol Biol 1:11-19); andor by random mutagenesis (See, e.g., Miller et al. (1992) A Short Course in Bacterial
Genetics, CSHL Press, Cold Spring Harbor, N.Y.; and
Greener et al. (1994) Strategies in Mol. Biol. 7:32-34).
[0129] In some embodiments, a transfection array (e.g.,
2-D andor 3-D array) of the present invention utilizes a
library of small gene fragments (e.g., sequences that encode
dominant-acting synthetic genetic elements (SGEs) (e.g.,
molecules that interfere with the function of genes from
which they are derived (antagonists) or that are dominant
constitutively active fragments (agonists) of such genes)).
SGEs that can be identified by the subject method include, but
are not limited to, polypeptides, inhibitory antisense RNA
molecules (e.g., siRNAs, shRNAs, snRNAs, etc.), ribozymes,
nucleic acid decoys, and small peptides.
[0130] In some embodiments, an SGE is identified using
the compositions andmethods ofthe present invention. These
function to inhibit the function of an
genetic elements mi&
u
u
endogenous gene at the level of nucleic acid expression a n d
or translation (e.g., by an antisense or decoy mechanism.
Alternatively, the synthetic genetic elements might encode a
polypeptide that is inhibitory through a mechanism of interference at the protein level (e.g., a dominant negative fragment of the native protein). In some embodiments, a synthetic
genetic element may function to enhance the function of an
endogenous gene (e.g., by encoding apolypeptide that retains
at least a portion of the bioactivity of the corresponding
endogenous gene, and may in particular instances be constitutively active).
[0131] In some embodiments, a synthetic genetic element
library is generated from total cDNA, that may be further

fragmented, and provided in the form of an expression library.
In some embodiments, the inserts in the library range from
about 100 base pairs (bp) to about 700 bp, In some embodiments, from about 20 bp to about 100 bp, and in some
embodiments, from about 30 bp to about 70 bp, although
shorter and longer sequences are contemplated.
[0132] For cDNA-derived libraries, the nucleic acid library
can be a normalized library containing roughly equal numbers of clones corresponding to each gene expressed in the
cell type from which it was made, without regard for the level
of expression of any gene.
[0133] Libraries can be generated to include both sense and
antisense coding (and non-coding sequences) sequences. In
some embodiments, expression (e.g., &anscription) of library
sequences in targethost cells creates antisense nucleic acids
(e.g., RNAs) that inhibit transcription of the corresponding
endogenous gene. In some embodiments, compositions and
methods described in U.S. Pat. No. 5,702,898 (hereby incorporated by reference in its entirety) for normalizing a cDNA
library constructed in a vector are utilized. In some embodiments, a sequence library is a subtractive cDNA library. Many
strategies
have been used to create subtractive libraries. and
u
can be readily adapted for use in the present method. For
example, use of directionally cloned cDNA libraries as starting material may be used (See, e.g., Palazzolo and Meyerowitz, (1987) Gene 52:197; Palazzolo et al. (1989) Neuron
3:527: Palazzolo et al. (1990)
,
, Gene 88:25). In some embodiments, a library of sequences is utilized that has been generated by providing an endonuclease restriction site at the 5' end
of an oligo(dT) primer. The restriction enzyme recognition
sequence does not affect the annealing of the 12-20 base
oligo(dT) primer to the mRNA, so the cDNA second strand
synthesized from the first strand template includes the new
recognition site added to the original 3' end of the coding
sequence. After second strand cDNA synthesis, a blunt ended
linker molecule containing a second restriction site (or a
partially double stranded linker adapter containing a protruding end compatible with a second restriction site) is ligated to
both ends of the cDNA. The site encoded by the linker is now
on both ends of the cDNA molecule, but only the 3' end of the
cDNA has the site introduced by the modified primer. Following the linker ligation step, the product is digested with
both restriction enzymes (or, if a partially double stranded
linker adapter was ligated onto the cDNA, with only the
enzyme that recognizes the modified primer sequence). A
population of cDNA molecules results which all have one
defined seauence on their 5' end and a different defined
sequence on their 3' end. In some embodiments, a sequence
library is generated according to a directional cloning strategy developed by Meissner et al. (1987) PNAS 84:4171) that
requires no sequence-specific modified primer, but rather a
double stranded palindromic BamHIIHindIII directional
linker having the sequence d(GCTTGGATCCAAGC),that is
ligated to a population of oligo(dT)-primed cDNAs, followed
by digestion of the ligation products with BamHI and HindIII.
The palindromic linker, when annealed to double stranded
form, includes an internal BamHI site (GGATCC) flanked by
4 of the 6 bases that define a HindIII site (AAGCTT). The
missing bases needed to complete a HindIII site are d(AA) on
the 5' end or d(TT) on the 3' end. Regardless of the sequence
to which this directional linker ligates, the internal BamHI
site will be present. However, HindIII can only cut the linker
if it ligates next to an d(AA):d(TT) dinucleotide base pair. In
an oligo(dT)-primed strategy, a HindIII site is always gener-
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ated at the 3' end of the cDNA after ligation to this directional
linker. For cDNAs having the sequence d(TT) at their 5' ends
(statistically 1 in 16 molecules), linker addition will also yield
a Hind111 site at the 5' end. However, because the 5' ends of
cDNA are heterogeneous due to the lack of processivity of
reverse transcriptases, cDNA products from every gene segment will be represented in the library.
[0134] In some embodiments, a sequence library encodes
molecules (e.g., nucleic acid sequences) that correspond to
regulatory elements of a gene and that can inhibit expression
of the gene by sequestering molecules important for transcription (e.g., transcriptional factors) thereby competing for
the necessary components to express the endogenous gene.
[0135] In some embodiments, a sequence library can be
generated by randomly fragmenting a single gene to obtain a
random fragment expression library derived exclusively from
the gene of interest. As a practical matter, such a library
contains a much greater variety of sequences from the gene of
interest than will a random fragment library prepared from
total cDNA.
[0136] In some embodiments, a purified DNA corresponding to a gene or genome to be suppressed (e.g., within cells
transfected in an array of the present invention) is first randomly fragmented by enzymatic, chemical, or physical procedures. In some embodiments, random fragments of DNA
are produced by treating the DNA with a nuclease, such as
DNase I. In some embodiments, the random DNA fragments
can be incorporated as inserts in a sequence library. DNase I
partial digestion and library construction are described generally in Molecular Cloning, A Laboratory Manual, Sambrook et al., Eds., Cold Spring Harbor Laboratory, Cold
Spring Harbor, N.Y. (1989). In some embodiments, sequence
fragment are expressed as part of a fusion protein. In some
embodiments, the inserted sequence fragment alone may be
expressed. In another embodiment, ribozyme-encoding
sequences may be inserted directly adjacent to the insert to
allow for selection of most efficient ribozyme-antisense
clones. In still other embodiments the sequence library (e.g.,
gene suppression element library) may be further modified by
vrocedures known in the art. The
random muta~enesis
u
inserted fragments may be expressed from either a constitutive or an inducible promoter.
[0137] In some embodiments, compositions and methods
of the present invention utilize a library encoding a variegated
population of small peptides (e.g., 4-25 amino acid residues
in length). The library can be generated from coding
sequences of total cDNA, or single genes, or can be random or
semi-random in sequence.
[0138] In some embodiments, compositions and methods
of the present invention utilize a transfection array that (e.g.,
when a nucleic acid sequence is transcribed in the host cell)
gives rise to double stranded RNA (e.g, for use in identifying
dsRNA constructs that produce a particular phenotype by
RNA interference).
[0139] Libraries of coding sequences, whether encoding
random peptides or full length proteins, may be expressed in
many ways, including as portions of chimeric (e.g., fusion)
proteins. In some instances it may be necessary to introduce
an unstructured polypeptide linker region between portions
of a chimeric protein derived from different proteins. The
linker may facilitate enhanced flexibility of the chimeric protein allowing each portion to fold correctly and retain appropriate biological activity in the host cell. The linker can be of
natural origin, such as a sequence determined to exist in

.

random coil between two domains of a vrotein. Altemativelv.,
the linker can be of synthetic origin. In some embodiments,
naturally occurring unstructured linkers of human origin are
preferred (e.g., because they reduce the risk of immunogenicity). In some embodiments, a fusion protein may comprise
a secretion signal sequence (e.g., where secretion of a protein
is desired).
[0140] The present invention is not limited by the number
of different transfection molecules presented in any particular
array (e.g., in any particular transfection zoneispot or on any
give surface of an array).
[0141] In some embodiments, a transfection cell array provides, in a single array, at least 10 different sequences, more
preferably at least 100,1000or even 10,000 different, discrete
types of transfectionmolecules (e.g., nucleic acid sequences).
In some embodiments, more than 10,000 or less than 10
different sequences are provided. In some embodiments,
transfection molecules are arrayed in an addressable fashion,
suchas rows and columns (e.g., where the substrate is a planar
surface).
[0142] The present invention contemplates the formation
of arrays with a plurality of transfection zonesispots on a
substrate surface (e.g., for both 2-D and 3-D arrays). In some
embodiments, a substrate surface has about 10,000 transfection zonesispots in a one centimeter square area. In some
embodiments, a transfection array provides a density of at
least 1000 different transfection zonesispots per square centimeter, and more preferably at least 5000, 8000, 10000,
100000, or more transfection zonesispots. In some embodiments, lower or higher densities of transfection zonesispots
are utilized.
[0143] As described herein, the present invention provides
the presentation of two or more different transfection molecules at any given spotitransfection zone described herein
(e.g. for co-transfection andor co-expression of the two or
more molecules in the same cells). Co-transfections can be
performed with transfected cell microarrays if the solution
spotted on the surface where reverse transfection occurs (e.g.,
in a 2-D array), or if the crosslinkable biopolymer and cells
are mixed and (e.g., in a 3-D array) contains more than one
plasmid or nucleic acid construct. The present invention contemplates the transfection of 2 or more, 10 or more, 50 or
more, 100 or more transfection molecules within any given
transfection zone.
[0144] In some embodiments, the ability to transfect two or
more transfection molecules into cells in a cell arrav of the
present invention provides a variety of uses. These include,
but are not limited to, the ability to infer the expression of a
gene product by detecting the expression of a co-transfected
plasmid encoding a marker protein (e.g. GFP, luciferase,
beta-galactosidase, or any protein to which a specific antibody is available), express all the components of a multisubunit complex (e.g. the T-cell receptor) in the same cells,
express all the components of a signal transduction pathway
(e.g. MAP kinase pathway) in the same cells, and express all
the components of a pathway that synthesizes a small molecule (e.g. intracellular antibodies, etc). In addition, the
capacity to co-transfect allows the creation of microarrays
with combinatorial combinations of co-expressed plasmids.
This capacity is particularly useful for implementing mammalian two-hybrid assays in which plasmids encoding bait
and prey proteins are co-transfected into the same cells by
spotting them in one feature of the microarray.
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[0145] The capacity to co-transfect is also useful when the
goal is to promote differentiation of the transfected cells
along a certain tissue lineage. For example, combination of
genes can be expressed in a stem cell or early progenitor cell
that may alter the differentiation of the cells (e.g., into endothelial, liver, heart, pancreatic, lymphoid, islet, brain, lung,
kidney or other cell types). In this fashion, arrays can be made
with primary-like cells that can be used to examine interactions of protein or small molecules that are cell-type specific.
[0146] Furthermore, transfection molecules may be introduced in specific locations on or within a 2-D or 3-D array,
respectively. For example, combinations of cDNAs can be
printed in different patterns on a substrate surface or be made
to be included in a plurality of spatially isolated crosslinked
biopolymers comprising cells and transfection molecules.
Exemplary patterns include, but are not limited to, bulls-eyes,
squares, rectangles of varying heights and widths, and lines of
single cell thickness. By placing (e.g., in particular patterns)
combinations of cDNAs that cause differentiation of cells
into different tissue types, this technology can be used to
obtain arrays with distinct cell types in distinct locations. This
capacity can be useful when trying to create tissue-like structures on the array, such as blood capillaries andor stromal
structures, or when studying the response of one cell type to
the protein secretions of another cell type. For example, a
secreting cell type can be created in the center of a bulls-eye
pattern and responder cell types of different tissues can be
created on the edge of bulls-eye. The response of the
responder cells to the secretions of the center cell can then be
examined (e.g., utilizing compositions and methods
described herein).
[0147] Arrays containing mixtures of plasmids at each
transfection zone can be constructed by mixing plasmids
before fixation to the substrate surface (e.g., printing, printing
in serial, printing with masks, or printing withpatternedprintheads) or before mixing a crosslinking agent to a composition
comprising a crosslinkable biopolymer, cells and transfection
molecules. For example, plasmids could be mixed in a container (e.g., before printing and printed as a homogenous
mixture).
[0148] A carrier andor biopolymer useful in the compositions and methods of the present invention can be, for
example, gelatin or an equivalent thereof. In certain embodiments, the carrier is a hydrogel, such as polycarboxylic acid,
cellulosic polymer, polyvinylpyrrolidone, maleic anhydride
polymer, polyamide, polyvinyl alcohol, or polyethylene
oxide.
[0149] The present invention is not limited by the type of
substrate surface to which transfection molecules are
attached (e.g., for 2-D transfection arrays) or to which 3-D
components (e.g., a crosslinkable biopolymer comprising
transfection molecules and cells) are attached.
[0150] Any suitable surface that can be used to affix mixtures of the present invention to its surface can be used. For
example, the surface can be glass, plastics (such as polytetrafluoroethylene, polyvinylidenedifluoride, polystyrene,
polycarbonate, polypropylene), silicon, metal, (such as gold),
membranes (such as nitrocellulose, methylcellulose, PTFE or
cellulose), paper, biomaterials (such as protein, gelatin, agar),
tissues (suchas skin, endothelial tissue, bone, cartilage), minerals (such as hydroxylapatite, graphite) andor a combination of the same. Additional compounds may be added to the
base material of the surface to provide functionality. For
example, scintillants can be added to a polystyrene substrate

to allow Scintillation Proximity Assays to be performed. The
substrate may be a porous solid support or non-porous solid
support. The surface can have concave or convex regions,
patterns of hydrophobic or hydrophilic regions, diffraction
gratings, channels or other features. The scale of these features can range from the meter to the nanometer scale. For
example, the scale can be on the micron scale for microfluidics channels or other MEMS features or on the nanometer
scale for nanotubes or buckyballs. The surface can be planar,
planar with raised or sunken features, spherical (e.g. optically
encoded beads), fibers (e.g. fiber optic bundles), tubular (both
interior or exterior), a 3-dimensional network (such as interlinking rods, tubes, spheres) or other shapes. The surface can
be part of an integrated system. For example, the surface can
be the bottom of a microtitre dish, a culture dish, andor a
culture chamber. Other components, such as lenses, gratings,
and electrodes, can be integrated with the surface. In general,
the material of the substrate and geometry of the array will be
selected based on criteria that it be useful for automation of
array formation, culturing andor detection of cellular phenotype.
[0151] In still other embodiments, the solid support is a
microsphere (bead), especially a FACS sortable bead. In
some embodiments, each bead is an individual transfection
zoneispot (e.g., having a homogenous population of target
seauences and distinct from most other beads in the mixture.
and one or more tags that can be used to the identify any given
bead and therefore the sequence it displays). The identity of
any given sequence that can induce a FACS-detectable
change in cells that adhere to the beads can be readily determined from the tag(s) associate with the bead. For example,
the tag can be an electrophoric tagging molecules that are
used as a binary code (See, e.g., Ohlmeyer et al. (1993) PNAS
90:10922-10926). Exemplary tags are haloaromatic alkyl
ethers that are detectable as their trimethylsilyl ethers at less
than femtomolar levels by electron capture gas chromatography (ECGC). Variations in the length of the alkyl chain, as
well as the nature and position of the aromatic halide substituents, may also be utilized. In some embodiments, a
sequence is attached to a photocleavable linker and the tag is
attached through a catechol ether linker via carbene insertion
into the bead matrix (See, e.g., Nestler et al. (1994) J. Org.
Chem. 59:4723-4724). This orthogonal attachment strategy
permits the FACS sorting of the cellhead entities and subsequent decoding by ECGC after oxidative detachment of the
tag sets from isolated beads. In other embodiments, the beads
can be tagged with two or more fluorescently active molecules, and the identity of the bead is defined by the ratio of
the various fluorophores.
[0152] In some embodiments, the transfection array can be
disposed on the end of a fiber optic system, such as a fiber
optic bundle. Each fiber optic bundle contains thousands to
millions of individual fibers depending on the diameter of the
bundle. Changes in the phenotype of cells applied to the
transfection array can be detected spectrometrically by conductance or transmittance of light over the spatially defined
optic bundle. An optical fiber is a clad plastic or glass tube
wherein the cladding is of a lower index of refraction than the
core of the tube. When a plurality of such tubes are combined,
a fiber optic bundle is produced. The choice of materials for
the fiber optic will depend at least in part on the wavelengths
at which the spectrometric analysis of the transfected cells is
to be accomplished.
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[0153] In some embodiments, a substrate surface can be
coated with. for examvle., a cationic moietv. The cationic
moiety can be any positively charged species capable of electrostatically binding to negatively charged polynucleotides.
Preferred cationic moieties for use in the carrier are polycations, such as polylysine (e.g., poly-L-lysine), polyarginine,
polyomithine, spermine, basic proteins such as histones (See,
e.g., Chen et al. (1994) FEBS Letters 338:167-169), avidin,
protamines (see e.g., Wagner et al. (1990) PNAS 87: 34103414), modified albumin (i.e., N-acylurea albumin) (See e.g.,
Huckett et al. (1990) Chemical Pharmacology 40: 253-263),
and polyamidoamine cascade polymers (See e.g., Haensler et
al. (1993) Bioconjugate Chem. 4:372-379). Apreferredpolycation is polylysine (e.g., ranging from 3,800 to 60,000 daltons). Alternatively, the surface itself can be positively
charged (e.g., gamma amino propyl silane or other alkyl
silanes).
[0154] The substrate surface can also be coated with molecules for additional functions. For example, molecules can
be capture reagents such as antibodies, biotin, avidin, NiNTA to bind epitopes, avidin, biotinylted molecules, or 6-His
tagged molecules. Alternatively, the molecules can be culture
reagents such as extracellular matrix, fetal calf serum, collagen, etc.
[0155] In some embodiments, once a microarrays of transfected cells have formed (e.g., cDNAs in transfection zones1
spots have entered cells and the cells have expressed the
encoded gene products), the microarrays can be transferred
onto a variety of surfaces. Surfaces can be flexible or nonflexible and porous or non-porous. The surfaces can be flat or
patterned with concave or convex regions, patterns of hydrophobic or hydrophilic regions, diffraction gratings, channels
or other features. The scale of these features can range from
the meter to the nanometer scale. Examples of surfaces
include, but are not limited to, glass, plastics (such as polytetrafluoroethylene, polyvinylidenedifluoride, polystyrene,
polycarbonate, polypropylene), silicon, metal, (such as gold),
membranes (such as nitrocellulose, methylcellulose, PTFE or
cellulose, polyvinylidene fluoride (PVDF)), paper, biomaterials (such as protein, gelatin, agar), tissues (such as skin,
endothelial tissue, bone, cartilage), minerals (such as
hydroxylapatite, graphite). Furthermore, many of these surfaces can be derivatized to provide additional functionalities.
For example, scintillants can be added to a polystyrene substrate to allow Scintillation Proximity Assays to be performed. In another example, nitrocellulose membranes can
be covalently modified with metal chelators that immobilize
metals, such as nickel or cobalt, and allow the selective binding of proteins carrying a specific amino acid sequence, such
as a hexa-histidine tag.
[0156] In some embodiments, transfers are performed such
that the entire cellular material on the microarray is transferred (e.g., both the endogenous and recombinant materials
made by the cells (e.g., RNA or protein) are transferred); or
such that only the recombinant material is transferred. In
some embodiments, the transfer of the microarray to another
surface is accomplished by directly contacting themicroarray
to the other surface and allowing the material to move to the
new surface under the influence of a force, such as capillary
forces (e.g., commonly referred to as "blotting"), electric or
magnetic fields, vacuum suction forces, or other forces. The
material may bind to thelnew surface through an interaction
mediated by hydrophobic, hydrophillic, Van der Waals, ionic
or other forces, or through specific receptor-ligand interac-

.

tions (e.g. antibody-epitope interactions) or by becoming
entangled in the molecular structure of the other surface.
[0157] The ability to transfer cellular material from the
microarrays to another surface has many potential uses.
These include, but are not limited to, the capacity to detect
cellular phenotypes or protein properties using techniques
normally performed on specific surfaces and the capacity to in
parallel purify the recombinant gene products expressed in
the microarray. Examples of techniques normally performed
on specific surfaces include western blotting, far-western
blotting, southwestern blotting, surface plasmon resonance
(SPR), mass spectroscopy, and others. These techniques normally require the immobilization of native or denatured proteins on nitrocellulose, nylon, paper, polyvinylidene fluoride
(PVDF), or gold or other metal surfaces or membranes.
Southwestern blotting is used to detect the interaction of a
nucleic acid (such as DNA or RNA) with a protein. After
transfer to an appropriate membrane, microarrays of cells
expressing a collection of DNA binding proteins, such as
transcription factors, can be used to identify binding proteins
for genomic DNA sequence elements.
[0158] The transfer of microarrays to other surfaces is also
useful for the in parallel purification of the recombinant proteins expressed on the microarray. The binding of proteins or
small molecules with the microarray can be detected with
autoradiography, fluorescence, mass spectroscopy,immunofluorescence, or calorimetry.
[0159] The present invention is not limited by the type of
cells utilized in a transfection cell array of the present invention. Indeed, a variety of cells may be utilized.
[0160] Examples of host cells for generating arrays of the
present invention include prokaryotes, yeast, or higher
eukaryotic cells, including plant and animal cells, especially
mammalian cells. Prokaryotes include gram negative or gram
positive organisms.
[0161] In some embodiments, compositions and methods
of the present invention method utilize cells derived from
higher eukaryotes (e.g., metazoans, mammalian cells, primate cells andlor human cells). Other species of mammalian
cells that may be utilized include canine, feline, bovine, porcine, mouse and rat. For instance, such cells can be hematopoietic cells, neuronal cells, pancreatic cells, hepatic cells,
chondrocytes, osteocytes, or myocytes. The cells can be fully
differentiated cells or progenitorlstem cells. The cells can be
derived from normal or diseased tissue, from differentiated or
undifferentiated cells, from embryonic or adult tissue. The
cells maybe dispersed in culture, or can be tissues samples
containing multiple cells that retain some of the microarchitecture of the organ.
[0162] In some embodiments, a transfection array of the
present invention is used to transfect a cell that can be cocultured with a target cell. A biologically active protein
secreted by the cells expressing nucleic acids (e.g., genes)
from the transfection array can diffuse to neighboring target
cells and induce a particular biological response (e.g., proliferation or differentiation, or activation of a signal transduction pathway (e.g., that can be detected by phenotypic criteria)). Likewise, antagonists of a given factor can be selected
by the ability of the cell producing a functional antagonist to
protect neighboring cells from the effect of exogenous factor
added to the culture media. The host and target cells can be in
direct contact, or separated (e.g., by a cell culture insert).
[0163] If yeast cells are used, the yeast may be of any
species that are cultivable and in the transfection array can be
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maintained upon transfection. Suitable species include
Kluyverei lactis, Schizosaccharomyces pombe, and Ustilaqo
maydis; Saccharomyces cerevisiae is preferred. Other yeast
that can be used in practicing the present invention are Neurospora crassa, Aspergillus niger, Aspergillus nidulans,
Pichiapastoris, Candida tropicalis, and Hansenulapolymorpha. The term "yeast," as used herein, includes not only yeast
in a strictly taxonomic sense (i.e., unicellular organisms), but
also yeast-like multicellular fungi or filamentous fungi.
[0164] The choice of appropriate host cell can be influenced by the choice of detection signal. For instance, reporter
constructs can provide a selectable or screenable trait upon
gain-of-function or loss-of-function induced by a target
nucleic acid. The reporter gene may be an unmodified gene
already in the host cell pathway, or it may be a heterologous
gene (e.g., a "reporter gene construct" described herein). In
other embodiments, second messenger generation can be
measured directly in a detection step, such as mobilization of
intracellular calcium or phospholipid metabolism, in which
case the host cell should have an appropriate starting phenotype for activation of such pathways.
[0165] In some embodiments, host cells can be engineered
to express other recombinant genes. For instance, the host
cells can be engineered with a reporter gene construct, and the
ability of members of the transfection array to alter the level
of expression of the reporter gene can be characterized. For
example, a transfection array can be assessed for members
which encode transcriptional activators or transcriptional
repressors of the reporter gene, and may include native and
non-native sequences. For example, a host cell can be transfected with reporter gene construct including a promoter
sequence for which a protein which binds that sequence is
sought.
[0166] In some embodiments, a host cell can be engineered
so as to have a loss-of-function or gain-of-function phenotype, and the ability of members of the transfection array to
alter the phenotype assessed.
[0167] In some embodiments, a host cell is engineered to
express a recombinant cell surface receptor, and the transfection array might encode a variegated library of gene products
or peptides, and the ability of one or more members of that
library to induce or inhibit signal transduction by the receptor
is assessed. For example, the transfection array can provide a
library of secreted peptides, and the ability of a given peptide
to induce signal transduction is detected by the conversion of
the cell to an autocrine phenotype.
[0168] The present invention is not limited by the method
of detecting cellular characteristics (e.g., nucleic acid andor
protein expression, cellular signaling, division, etc.) in a 2-D
andor 3-D transfection array described herein.
[0169] A variety of methods can be used to detect the consequence of uptake, and in many embodiments, expression
(e.g., transcription) of sequences within cells (e.g., present in
a 2-D andor 3-D array of the present invention). In a general
sense, assays described herein provide means for determining
if the target sequence is able to confer a change in the phenotype of the cell relative to the same cell but which lacks the
target sequence. Such changes can be detected on a gross
cellular level, such as by changes in cell morphology (e.g.,
membrane ruffling, rate of mitosis, rate of cell death, mechanism of cell death, dye uptake, and the like). In other embodiments, changes to the cell's phenotype, if any, can be detected
by more focused means, such as the detection of the level of
a particular protein (e.g., a selectable or detectable marker), or

level of mRNA or second messenger). Changes in the cell's
phenotype can be determined by assaying reporter genes
(beta-galactosidase, green fluorescent protein, beta-lactamase, luciferase, chloramphenicol acetyl transferase), assaying enzymes, using immunoassays, staining with dyes (e.g.
DAPI, calcofluor), assaying electrical changes, characterizing changes in cell shape, examining changes in protein conformation, counting cell number, etc. Other changes of interest could be detected by methods such as chemical assays,
light microscopy, scanning electron microscopy, transmission electron microscopy, atomic force microscopy, confocal
microscopy, image reconstruction microscopy, scanners,
autoradiography, light scattering, light absorbance, NMR,
PET, patch clamping, calorimetry, mass spectrometry, surface plasmon resonance, andor time resolved fluorescence.
Data could be collected at single or multiple time points and
analyzed by the appropriate software (See, e.g., U.S. Patent
Application Publication No. 20030228601, hereby incorporated by reference in its entirety)).
[0170] In some embodiments, transcriptional activity
within a cell is detected andor measured by a transcription
product (e.g., by detecting transcriptional activation (or
repression) of an indicator gene(s)). Detection of the transcription product includes detecting the gene transcript,
detecting the product directly (e.g., by immunoassay) or
detecting an activity of the protein (e.g., such as an enzymatic
activity or chromogenic1fluorogenicactivity). The indicator
gene may be an unmodified endogenous gene of the host cell,
a modified endogenous gene, or a part of a completely heterologous construct (e.g., part of a reporter gene construct).
[0171] In some embodiments, the indicator gene is an
unmodified endogenous gene. For example, compositions
and methods of the present invention may detect the transcriptional level of one or more endogenous genes.
[0172] In some embodiments, a heterologous reporter gene
construct can be used to provide the function of an indicator
gene. Reporter gene constructs are prepared by operatively
linking a reporter gene with at least one transcriptional regulatory element (See, e.g., Example 1)
[0173] The present invention is not limited by any particular reporter gene construct. Many reporter genes and transcriptional regulatory elements are known to those of skill in
the art and others may be identified or synthesized by methods
known to those of skill in the art. Examples of reporter genes
include, but are not limited to CAT (chloramphenicol acetyl
transferase) (See, e.g., Alton andvapnek (1979), Nature 282:
864-869) luciferase, and other enzyme detection systems,
such as beta-galactosidase; firefly luciferase (See, e.g., deWet
et al. (1987), Mol. Cell. Biol. 7:725-737); bacterial luciferase
(See, e.g., Engebrecht and Silverman (1984), PNAS 1:41544158; Baldwin et al. (1984), Biochemistry 23:3-663-3667);
alkaline phosphatase (See, e.g., Toh et al. (1989) Eur. J. Biochem. 182:231-238, Hall et al. (1983) J. Mol. Appl. Gen.
2: 101), human placental secreted alkaline phosphatase (See,
e.g., Cullen and Malim (1992) Methods in Enzymol. 216:
362-368); beta-lactamase, and GST.
[0174] Transcriptional control elements for use in the
reporter gene constructs, or for modifying the genomic locus
of an indicator gene include, but are not limited to, promoters,
enhancers, and repressor and activator binding sites. Suitable
transcriptional regulatory elements may be derived from the
transcriptional regulatory regions of genes whose expression
is linked to the desired phenotype sought from the arrayed
library.
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[0175] In some embodiments, the reporter gene is a gene
whose expression causes a phenotypic change which is
screenable or selectable. If the change is selectable, the phenotypic change creates a difference in the growth or survival
rate between cells which express the reporter gene and those
which do not. If the change is screenable, fhe phenotype
change
creates a difference in some detectable characteristic
u
of the cells, by which the cells which express the marker may
be distinguished from those which do not. Selection is preferable to screening in that it can provide a means for amplifying from the cell culture those cells which express a test
polypeptide which is a receptor effector.
[0176] Many different types of information are contemplated to be generated using the compositions and methods of
the present invention. For example, binding partners for molecules such as drugs, hormones, interleukins, or secreted
proteins can be identified by incubating the compounds of
interest (test agents) with an array that overexpresses potential targets within each array feature or combinations of
potential targets within each cell of an array feature. Binding
can be detected by methods such as SPR, SPA, TRF, or
autoradiography.
[0177] An array can also be used to identify targets of an
organism's immune response to cancer, an infectious or
autoimmune disease, exposure to chemicals, or environmental changes. In some embodiments, the present invention
facilitates drug target discovery by permitting the identification of an endogenous gene wherein inhibition or activation
of the gene may be of therapeutic value. In some embodiments, loss of function of genes can be characterized. For
example, transcription arrays that give rise to dsRNA in the
host cell can be used to assess the loss-of-function of a particular gene (e.g., via RNAi or gene silencing (See, e.g., Fire
A (1999) Trends Genet. 15:358-363; Sharp P A (1999) Genes
Dev 13:139-141; Hunter C. (1999) Curr. Biol. 9:R440-R442;
Baulcombe D.C. (1999) Curr. Biol. 9:R599-R601; Vaucheret
et al. (1998) Plant J. 16:651-659)). In some embodiments, an
array of the present invention is utilized to characterize a gene
of interest.
[0178] In some embodiments, an array of the present invention is utilized to characterize candidate agents (e.g., for
therapeutics (e.g., proteins, small molecules, oligonucleotides, etc.). In some embodiments, arrays are used to characterize compound libraries andor potential drug candidates.
[0179] The ability of certain viruses to infect cells or enter
cells via receptor-mediated endocytosis, and to integrate into
host cell genome and express viral genes stably and efficiently have made them attractive candidates for the transfer
of nucleic acid sequences (e.g., transfection molecules) into
mammalian cells. In some embodiments, vectors of the
present invention are viral vectors (e.g., phage or andenovirus
vectors).
[0180] Although some viruses that can accept foreign
genetic material are limited in the number of nucleotides they
can accommodate and in the range of cells they infect, these
viruses have been demonstrated to successfully effect gene
expression. However, adenoviruses do not integrate their
genetic material into the host genome and therefore do not
require host replication for gene expression, making them
ideally suited for rapid, efficient, heterologous gene expression. Techniques for preparing replication-defective infective
viruses are well known in the art.
[0181] Of course, in using viral delivery systems, one will
desire to purify the virion sufficiently to render it essentially

free of undesirable contaminants, such as defective interfering viral particles or endotoxins and other pyrogens such that
it will not cause any untoward reactions in the cell, animal or
individual receiving the vector construct. A preferred means
of purifying the vector involves the use of buoyant density
gradients, such as cesium chloride gradient centrifugation.
[0182] A particular method for delivery of the expression
constructs involves the use of an adenovirus expression vector. Although adenovirus vectors are known to have a low
capacity for integration into genomic DNA, this feature is
counterbalanced by the high efficiency of gene transfer
afforded by these vectors. "Adenovirus expression vector" is
meant to include those constructs containing adenovirus
sequences sufficient to (a) support packaging of the construct
and (b) to ultimately express a tissue or cell-specific construct
that has been cloned therein.
[0183] The expressionvector comprises a genetically engineered form of adenovirus. Knowledge of the genetic organization or adenovirus, a 36 kb, linear, double-stranded DNA
virus, allows substitution of large pieces of adenoviral DNA
with foreign sequences up to 7 kb (See Grunhaus and Horwitz. 1992). In contrast to retrovirus. the adenoviral infection
of host cells does not result in chromosomal integration
because adenoviral DNA can replicate in an episomal manner
without potential genotoxicity. Also, adenoviruses are structurally stable, and no genome rearrangement has been
detected after extensive amplification.
[0184] Adenovirus is particularly suitable for use as a gene
transfer vector because of its mid-sized genome, ease of
manipulation, high titer, wide target-cell range and high
infectivity. Both ends of the viral genome contain 100-200
base pair inverted repeats (ITRs), which are cis elements
necessary for viral DNA replication and packaging. The early
(E) and late (L) regions of the genome contain different
transcription units that are divided by the onset of viral DNA
replication. The E l region (ElA and ElB) encodes proteins
responsible for the regulation of transcription of the viral
genome and a few cellular genes. The expression of the E2
region (E2A and E2B) results in the synthesis of the proteins
for viral DNA replication. These proteins are involved in
DNA replication, late gene expression and host cell shut-off
(Renan, 1990). The products of the late genes, including the
majority of the viral capsid proteins, are expressed only after
significant processing of a single primary transcript issued by
the maior late vromoter (MLP).
,
, The MLP (located at 16.8
map units (m.~.))
is particularly efficient during the late phase
of infection, and all the mRNA's issued from this promoter
possess a 5'-tripartite leader (TPL) sequence which makes
them preferred mRNA's for translation.
[0185] In a current system, recombinant adenovirus is generated from homologous
recombination between shuttle vecu
tor and provirus vector. Due to the possible recombination
between two proviral vectors, wild-type adenovirus may be
generated from this process. Therefore, it is critical to isolate
a single clone of virus from an individual plaque and examine
its genomic structure.
[0186] Generation and propagation of the current adenovirus vectors, which are replication deficient, depend on a
unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA
fragments and constitutively expresses E l proteins (EIA and
EIB; Graham et al., 1977). Since the E3 region is dispensable
from the adenovirus genome (Jones and Shenk, 1978), the
current adenovirus vectors, with the help of 293 cells, cany
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foreign DNA in either the El, the D3 or both regions (Graham
and Prevec, 1991). Recently, adenoviral vectors comprising
deletions in the E4 region have been described (U.S. Pat. No.
5,670,488, incorporated herein by reference).
[0187] In nature, adenovirus can package approximately
105% of the wild-type genome (Ghosh-Choudhury et al.,
1987), providing capacity for about 2 extra kb of DNA. Combined with the approximately 5.5 kb of DNA that is replaceable in the E l and E3 regions, the maximum capacity of the
current adenovirus vector is under 7.5 kb, or about 15% of the
total length of the vector. More than 80% of the adenovirus
viral genome remains in the vector backbone.
[0188] Helper cell lines may be derived from human cells
such as human embryonic kidney cells, muscle cells, hematopoietic cells or other human embryonic mesenchymal or epithelial cells. Alternatively, the helper cells may be derived
from the cells of other mammalian species that are permissive
for human adenovirus. Such cells include, e.g., Vero cells or
other monkey embryonic mesenchymal or epithelial cells. As
stated above, the preferred helper cell line is 293.
[0189] Racher et al. (1995) disclosedimprovedmethods for
culturing 293 cells and propagating adenovirus. In one format, natural cell aggregates are grown by inoculating individual cells into 1 liter siliconized spinner flasks (Techne,
Cambridge, UK) containing 100-200 ml of medium. Following stirring at 40 rpm, the cell viability is estimated with
trypan blue. In another format, Fibra-Cel microcarriers
(Bibby Sterlin, Stone, UK) (5 gll) is employed as follows. A
cell inoculum, resuspended in 5 ml of medium, is added to the
carrier (50 ml) in a 250 ml Erlenmeyer flask and left stationary, withoccasional agitation, for 1 to 4 h. Themedium is then
replaced with 50 ml of fresh medium and shaking initiated.
For virus production, cells are allowed to grow to about 80%
confluence, after which time the medium is replaced (to 25%
of the final volume) and adenovirus added at an MOI of 0.05.
Cultures are left stationary overnight, following which the
volume is increased to 100% and shaking commenced for
another 72 h.
[0190] Other than the requirement that the adenovirus vector be replication defective, or at least conditionally defective,
the nature of the adenovirus vector is not believed to be
crucial to the successful practice of the invention. The adenovirus may be of any of the 42 different known serotypes or
subgroups A-F. Adenovirus type 5 of subgroup C is the preferred starting material in order to obtain the conditional
replication-defective adenovirus vector for use in the present
invention. This is because Adenovirus type 5 is a human
adenovirus about which a great deal of biochemical and
genetic information is known, and it has historically been
used for most constructions employing adenovirus as a vector.
[0191] As stated above, the typical adenovirus vector
according to the present invention is replication defective and
will not have an adenovirus E l region. Thus, it will be most
convenient to introduce the transforming construct at the
position from which the El-coding sequences have been
removed. However, the position of insertion of the construct
within the adenovirus sequences is not critical to the invention. The polynucleotide encoding the gene of interest may
also be inserted in lieu of the deleted E3 region in E3 replacement vectors as described by Karlsson et al. (1986) or in the
E4 region where a helper cell line or helper virus complements the E4 defect.

-

[0192] Adenovirus growth and manipulation is known to
those of skill in the art, and exhibits broad host range in vitro
and in vivo. This goup of viruses can be obtained in high
titers, e.g., 10.sup.9to 10.sup.l 1 plaque-formingunits
and they are highly infective. The life cycle of adenovirus
does not require integration into the host cell genome. The
foreign genes delivered by adenovirus vectors are episomal
and, therefore, have low genotoxicity to host cells.
[0193] Adenovirus vectors have been used in eukaryotic
gene expression (Levrero et al., 1991; Gomez-Foix et al.,
1992) and vaccine development (Grunhaus and Honvitz,
1992; Graham and Prevec, 1992). Recombinant adenovirus
and adeno-associated virus (see below) can both infect and
transduce non-dividing human primary cells
[0194] Adeno-associated virus (AAV) is an attractive vector system for use in the cell transduction of the present
invention as it has a high frequency of integration and it can
infect nondividing cells, thus making it useful for delivery of
genes into mammalian cells, for example, in tissue culture
(Muzyczka, 1992) or in vivo. AAV has a broad host range for
infectivity (Tratschin et al., 1984; Laughlin et al., 1986; Lebkowski et al., 1988; McLaughlin et al., 1988). Details concerning the generation and use of rAAV vectors are described
inU.S. Pat. No. 5,139,941 andU.S. Pat.No. 4,797,368, each
incorporated herein by reference.
[0195] Studies demonstrating the use ofAAV in gene delivery include LaFace et al. (1988); Zhou et al. (1993); Flotte et
al. (1993); and Walshet al. (1994). Recombinant AAVvectors
have been used successfully for in vitro and in vivo transduction of marker genes (Kaplitt et al., 1994; Lebkowski et al.,
1988; Samulski et al., 1989; Yoder et al., 1994; Zhou et al.,
1994; Hermonat and Muzyczka, 1984; Tratschin et al., 1985;
McLaughlin et al., 1988) and genes involved in human diseases (Flotte et al., 1992; Luo et al., 1994; Ohi et al., 1990;
Walsh et al., 1994; Wei et al., 1994). Recently, anAAVvector
has been approved for phase I human trials for the treatment
of cystic fibrosis.
[0196] AAV is a dependent parvovirus in that it requires
coinfection with another virus (either adenovirus or a member of the herpes virus family) to undergo a productive infection in cultured cells (Muzvczka.
,
,
, 1992). In the absence of
coinfection with helper virus, the wild type AAV genome
integrates through its ends into human chromosome 19 where
it resides in a latent state as a provirus (Kotin et al., 1990;
Samulski et al., 1991). rAAV, however, is not restricted to
chromosome 19 for integration unless the AAV Rep protein is
also expressed (Shelling and Smith, 1994). When a cell carrying an AAV provirus is superinfected with a helper virus,
the AAV genome is "rescued" from the chromosome or from
a recombinant plasmid, and a normal productive infection is
established (Samulski et al., 1989; McLaughlin et al., 1988;
Kotin et al., 1990; Muzyczka, 1992).
[0197] Typically, recombinant AAV (rAAV) virus is made
by cotransfecting a plasmid containing the gene of interest
flanked by the two AAV terminal repeats (McLaughlin et al.,
1988; Samulski et al., 1989; each incorporated herein by
reference) and an expression plasmid containing the wild
type AAV coding sequences without the terminal repeats, for
examplepIM45 (McCarty et al., 1991; incorporatedherein by
reference). The cells are also infected or transfected with
adenovirus or plasmids carrying the adenovirus genes
required for AAV helper function. rAAV virus stocks made in
such fashion are contaminated with adenovirus which must
be physically separated from the rAAV particles (for
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example, by cesium chloride density centrifugatiorl). Alternatively, adenovirus vectors containing the AA\' coding
regions or cell lines containing the AAV coding regions and
some or all of the adenovirus helper genes could be used
(Yang et al., 1994; Clark et al., 1995). Cell lines canying the
rAAV DNA as an integrated provirus can also be used (Flotte
et al., 1995).
[0198] Retroviruses have promise as gene delivery vectors
due to their ability to integrate their genes into the host
genome, transferring a large amount of foreign genetic material, infecting a broad spectrum of species and cell types and
of being packaged in special cell-lines (Miller, 1993).
[0199] The retroviruses are a group of single-stranded RNA
viruses characterized by an ability to convert their RNA to
double-stranded DNA in infected cells by a process of
reverse-transcription (Coffin, 1990). The resulting DNA then
stably integrates into cellular chromosomes as a provirus and
directs synthesis of viral proteins. The integration results in
the retention of the viral gene sequences in the recipient cell
and its descendants. The retroviral genome contains three
genes, gag, pol, and env that code for capsid proteins, polymerase enzyme, and envelope components, respectively. A
sequence found upstream from the gag gene contains a signal
for packaging of the genome into virions. Two long terminal
repeat (LTR) sequences are present at the 5' and 3' ends of the
viral genome. These contain strong promoter and enhancer
sequences and are also required for integration in the host cell
genome (Coffin, 1990).
[0200] In order to construct a retroviral vector, a nucleic
acid encoding a gene of interest is inserted into the viral
genome in the place of certain viral sequences to produce a
virus that is replication-defective. In order to produce virions,
a packaging cell line containing the gag, pol, and env genes
but without the LTR and packaging components is constructed (Mann et al., 1983). When a recombinant plasmid
containing a cDNA, together with the retroviral LTR and
packaging sequences is introduced into this cell line (by calcium phosphate precipitation for example), the packaging
sequence allows the RNA transcript of the recombinant plasmid to be packaged into viral particles, which are then
secreted into the culture media (Nicolas and Rubenstein,
1988; Temin, 1986; Mannet al., 1983).Themedia containing
the recombinant retroviruses is then collected, optionally
concentrated, and used for gene transfer. Retroviral vectors
are able to infect a broad variety of cell types. However,
integration and stable expression require the division of host
cells (Paskind et al., 1975).
[0201] Concern with the use of defective retrovirus vectors
is the potential appearance of wild-type replication-competent virus in the packaging cells. This can result from recombination events in which the intact sequence from the recombinant virus inserts upstream from the gag, pol, env sequence
integrated in the host cell genome. However, new packaging
cell lines are now available that should greatly decrease the
likelihood of recombination (Markowitz et al., 1988; Hersdorffer et al., 1990).
[0202] Gene delivery using second generation retroviral
vectors has been reported. Kasahara et al. (1994) prepared an
engineered variant of the Moloney murine leukemia virus,
that normally infects only mouse cells, and modified an envelope protein so that the virus specifically bound to, and
infected, human cells bearing the erythropoietin (EPO)
receptor. This was achieved by inserting a portion of the EPO

sequence into an envelope protein to create a chimeric protein
with a new binding specificity.
[0203] Other viral vectors may be employed as expression
constructs in the present invention. Vectors derived from
viruses such as vaccinia virus (Ridgeway, 1988; Baichwal
and Sugden, 1986; Coupar et al., 1988), sindbis virus,
cytomegalovirus and herpes simplex virus may be employed.
They offer several attractive features for various mammalian
cells (Friedmann, 1989; Ridgeway, 1988; Baichwal and Sugden, 1986; Coupar et al., 1988; Honvich et al., 1990).
[0204] With the recent recognition of defective hepatitis B
viruses, new insight was gained into the structure-function
relationship of different viral sequences. In vitro studies
showed that the virus could retain the ability for helperdependent packaging and reverse transcription despite the
deletion of up to 80% of its genome (Honvich et al., 1990).
This suggested that large portions of the genome could be
replaced with foreign genetic material. Chang et al. recently
introduced the chloramphenicol acetyltransferase (CAT)
gene into duck hepatitis B virus genome in the place of the
polymerase, surface, and pre-surface coding sequences. It
was cotransfected with wild-type virus into an avian
hepatoma cell line. Culture media containing high titers of the
recombinant virus were used to infect primary duckling hepatocytes. Stable CAT gene expression was detected for at least
24 days after transfection (Chang et al., 1991).
[0205] In certain further embodiments, the vector will be
HSV. A factor that makes HSV an attractive vector is the size
and organization of the genome. Because HSV is large, incorporation of multiple genes or expression cassettes is less
problematic than in other smaller viral systems. In addition,
the availability of different viral control sequences with varying performance (temporal, strength, etc.) makes it possible
to control expression to a greater extent than in other systems.
It also is an advantage that the virus has relatively few spliced
messages, further easing genetic manipulations. HSV also is
relatively easy to manipulate and can be grown to high titers.
Thus, delivery is less of a problem, both in terms of volumes
needed to attain sufficient MOI and in a lessened need for
repeat dosings.
[0206] In still further embodiments of the present invention, the nucleic acids to be delivered are housed within an
infective virus that has been engineered to express a specific
binding ligand. The virus particle will thus bind specifically
to the cognate receptors of the target cell and deliver the
contents to the cell. A novel approach designed to allow
specific targeting of retrovirus vectors was recently developed based on the chemical modification of a retrovirus by the
chemical addition of lactose residues to the viral envelope.
This modification can permit the specific infection of hepatocytes via sialoglycoprotein receptors.
[0207] Another approach to targeting of recombinant retroviruses was designed in which biotinylated antibodies
against a retroviral envelopeprotein and against a specific cell
receptor were used. The antibodies were coupled via the
biotin components by using streptavidin (Roux et al., 1989).
Using antibodies against major histocompatibility complex
class I and class I1 antigens, they demonstrated the infection
of a variety of human cells that bore those surface antigens
with an ecotropic virus in vitro (Roux et al., 1989).
[0208] In various embodiments of the invention, nucleic
acid sequence encoding a fusion protein is delivered to a cell
as an expression construct. In order to effect expression of a
gene construct, the expression construct must be delivered
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into a cell. As described herein, one mechanism for delivery is
via viral infection, where the expression construct is encapsidated in an infectious viral particle. However, several nonviral methods for the transfer of expression constructs into
cells also are contemplated by the present invention. In one
embodiment of the present invention, the expression construct may consist only of naked recombinant DNA or plasmids (e.g., vectors comprising nucleic acid sequences of the
present invention). Transfer of the construct may be performed by any of the methods mentioned which physically or
chemically permeabilize the cell membrane. Some of these
techniques may be successfully adapted for invivo or ex vivo
use, as discussed below.
[0209] In a further embodiment of the invention, the
expression construct may be entrapped in a liposome. Liposomes are vesicular structures characterized by a phospholipid bilayer membrane and an inner aqueous medium. Multilamellar liposomes have multiple lipid layers separated by
aqueous medium. They form spontaneously when phospholipids are suspended in an excess of aqueous solution. The
lipid components undergo self-rearrangement before the formation of closed structures and entrap water and dissolved
solutes between the lipid bilayers (Ghosh and Bachhawat,
1991). Also contemplated is an expression construct complexed with Lipofectamine (Gibco BRL).
[0210] Liposome-mediated nucleic acid delivery and
expression of foreign DNA in vitro has been very successful
(Nicolau and Sene, 1982; Fraley et al., 1979; Nicolau et al.,
1987). Wong et al. (1980) demonstrated the feasibility of
liposome-mediated delivery and expression of foreign DNA
in cultured chick embryo, HeLa and hepatoma cells.
[0211] In certain embodiments of the invention, the liposome may be complexed with a hemagglutinating virus
(HVJ). This has been shown to facilitate fusion with the cell
membrane and promote cell entry of liposome-encapsulated
DNA (Kaneda et al., 1989). In other embodiments, the liposome may be complexed or employed in conjunction with
nuclear non-histone chromosomal proteins (HMG-1) (Kato
et al., 1991). In yet further embodiments, the liposomemay be
complexed or employed in conjunction with both HVJ and
HMG-1. In other embodiments, the delivery vehicle may
comprise a ligand and a liposome. Where a bacterial promoter
is employed in the DNA construct, it also will be desirable to
include within the liposome an appropriate bacterial polymerase.
[0212] Certain receptor-mediated gene targeting vehicles
comprise a cell receptor-specific ligand and a DNA-binding
agent. Others comprise a cell receptor-specific ligand to
which the DNA construct to be delivered has been operatively
attached. Several ligands have been used for receptor-mediated gene transfer (Wu and Wu, 1987; Wagner et al., 1990;
Perales et al., 1994; Myers, EPO 0273085), which establishes
the operability of the technique. In certain aspects of the
present invention, the ligand will be chosen to correspond to
a receptor specifically expressed on the EOE target cell population.
[0213] In other embodiments, the DNA delivery vehicle
component of a cell-specific gene targeting vehicle may comprise a specific binding ligand in combination with a liposome. The nucleic acids to be delivered are housed within the
liposome and the specific binding ligand is functionally
incorporated into the liposome membrane. The liposome will
thus specifically bind to the receptors of the target cell and
deliver the contents to the cell. Such systems have been shown

to be functional using systems in which, for example, epidermal growth factor (EGF) is used in the receptor-mediated
delivery of a nucleic acid to cells that exhibit upregulation of
the EGF receptor.
[0214] In still further embodiments, the DNA delivery
vehicle component of the targeted delivery vehicles may be a
liposome itself, which will preferably comprise one or more
lipids or glycoproteins that direct cell-specific binding. For
example, Nicolau et al. (1987) employedlactosyl-ceramide, a
galactose-terminal asialganglioside, incorporated into liposomes and observed an increase in the uptake of the insulin
gene by hepatocytes. It is contemplated that the tissue-specific transforming constructs of the present invention can be
specifically delivered into the target cells in a similar manner.
[0215] Homologous recombination (Koller and Smithies,
1992) allows the precise modification of existing genes, overcomes the vroblems of vositional effects and insertional inactivation, and allows the inactivation of specific genes, as well
as the replacement of one gene for another. Methods for
homologous recombination are described in U.S. Pat. No.
5,6 14,396, incorporated herein in its entirety by reference.
Thus. in some embodiments. host cells utilized in an arrav of
the present invention are generated via homologous recombination. Homologous recombination relies, like antisense,
on the tendency of nucleic acids to base pair with complementary sequences. In this instance, the base pairing serves to
facilitate the interaction of two separate nucleic acid molecules so that strand breakage and repair can take place. In
other words, the "homologous" aspect of the method relies on
sequence homology to bring two complementary sequences
into close proximity, while the "recombination" aspect provides for one complementary sequence to replace the other by
virtue of the breaking of certain bonds and the formation of
others.
[0216] In some embodiments, a candidate agent can be
added to one or more transfection zones (e.g., to alter expression andor activity). As used herein, a "candidate agent" may
be any agent that potentially inhibits or enhances transcription, translation or the like within a cell, including, but not
limited to, a drug, a pharmaceutical, a small molecule, and an
compound. For example, the candidate agent may be a protein
or fragment thereof, a small molecule, a chemical, or even a
nucleic acid molecule. Using lead compounds to help develop
improved compounds is know as "rational drug design" and
includes not onlv comvarisons with know inhibitors and
enhancers of protein folding/solubility, but predictions relating to the structure of target molecules. Thus, using compositions and methods of the present invention, it is possible to
identify candidate agents that have the ability to alter cellular
activities (e.g., growth, transcription, cellular signaling, etc.).
[0217] The goal of rational drug design is to produce structural analogs of biologically active polypeptides or target
compounds. By creating such analogs, it is possible to fashion
drugs, which are more active or stable than the natural molecules, which have different susceptibility to alteration or
which may affect the function of various other molecules. In
one approach, it is possible to generate a three-dimensional
structure for a target molecule, or a fragment thereof. This
could be accomplished by x-ray crystallography, computer
modeling or by a combination of both approaches.
[0218] It also is possible to use antibodies to ascertain the
structure of a candidate enhancer or inhibitor. In principle,
this approach yields a pharmacore upon which subsequent
drug design can be based. It is possible to bypass protein
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crystallography altogether by generating anti-idiotypic antibodies to a functional, pharmacologically active antibody. As
a mirror image of a mirror image, the binding site of antiidiotype would be expected to be an analog of the original
antigen. The anti-idiotype could then be used to identify and
isolate peptides from banks of chemically- or biologicallyproduced peptides. Selected peptides would then serve as the
pharmacore. Anti-idiotypes may be generated using the
methods described herein for producing antibodies, using an
antibody as the antigen.
[0219] On the other hand, one may simply acquire, from
various commercial sources, small molecule libraries that are
believed to meet the basic criteria for useful drugs in an effort
to "brute force" the identification of useful candidate agents.
Screening of such libraries, including combinatorially generated libraries (e.g., peptide libraries), is a rapid and efficient
way to screen large number of related (and unrelated) agents
for activity. Combinatorial approaches also lend themselves
to rapid evolution of potential drugs by the creation of second,
third and fourth generation compounds modeled of active, but
otherwise undesirable compounds.
[0220] Candidate agents may include fragments or parts of
naturally-occurring compounds, or may be found as active
combinations of known compounds, which are otherwise
inactive. It is proposed that compounds isolated from natural
sources, such as animals, bacteria, fungi, plant sources,
including leaves and bark, and marine samples may be
assayed as candidates for the presence of potentially useful
pharmaceutical agents. It will be understood that the agents
(e.g., pharmaceuticals) to be screenedcouldalso be derivedor
synthesized from chemical compositions or man-made compounds. Thus, it is understood that the candidate agent identified by the present invention may be any peptide, polypeptide, polynucleotide, small molecule inhibitors or any other
chemicals or compounds (e.g., that may be designed through
rational drug design starting from known inhibitors or
enhancers).
[0221] Other potential agents include antisense molecules,
ribozymes, and antibodies (including single chain antibodies), each of which would be specific for the target molecule.
Such compounds are described in greater detail elsewhere in
this document. For example, an antisense molecule that
bound to a translational or transcriptional start site, or splice
junctions, would be ideal candidate inhibitors.
[0222] In addition to the modulating agents (e.g., compounds) initially identified, other sterically similar compounds may be formulated to mimic the key portions of the
structure of the modulators. Such agents (e.g., compounds),
which may include peptidomimetics of peptide modulators,
may be used in the same manner as the initial modulators.
[0223] The invention also provides a method for screening
for mutations in a host cell, or in a target protein sequence
(e.g., that alters transcription in a cell). For example, cells
comprising a transcription molecule of the present invention
and those host cells that
can be treated with a mutagen.
u
,
display an increase in growth (e.g., rate or abundance) identified. A "mutagen" is intended to include, but not be limited
to chemical mutagens such as ethyl methane sulphonate,
N-methyl-N'-nitroso-guanidineand nitrous acid as well as
physical agents such as ionizing radiation.
[0224] In an alternative embodiment, mutations can be
introduced into a polynucleotide sequence encoding a target
protein. The altered polynucleotide is then tested to determine
whether the solubility of the target protein is changed (e.g., as

monitored by growth in a selective environment, e.g., in the
presence of ampicillin). Such mutations include, but are not
limited to, mutations induced by a mutagen; site directed
mutations that alter specific amino acid residues such as
mutation of cysteine residues to eliminate disulfide bonds;
deletions that remove sets of specific amino acids such as
deletion of a continuous stretch of hydrophobic amino acids;
and fusions of the target protein to a second, particularly
soluble protein. In each case, the solubility of the target protein is assessed by determining growth of the host cells in a
selective environment.
[0225] Where employed, mutagenesis can be accomplished by a variety of standard, mutagenic procedures. Mutation can involve modification of the nucleotide sequence of a
single gene, blocks of genes or whole chromosome. Changes
in single genes may be the consequence of point mutations
which involve the removal, addition or substitution of a single
nucleotide base within a DNA sequence, or they may be the
consequence of changes involving the insertion or deletion of
large numbers of nucleotides.
[0226] Mutations can arise spontaneously as a result of
events such as errors in the fidelity of DNA replication or the
movement of transposable genetic elements (transposons)
within the genome. They also are induced following exposure
to chemical or physical mutagens. Such mutation-inducing
agents include ionizing radiations, ultraviolet light and a
diverse array of chemical such as alkylating agents and polycyclic aromatic hydrocarbons all of which are capable of
interacting either directly or indirectly (generally following
some metabolic biotransformations) with nucleic acids. The
DNA lesions induced by such environmental agents may lead
to modifications of base sequence when the affected DNA is
replicated or repaired and thus to a mutation. Mutation also
can be site-directed through the use of particular targeting
methods.
Random Mutagenesis.
[0227] i) Insertional Mutagenesis
[0228] Insertional mutagenesis is based on the inactivation
of a gene via insertion of a known DNA fragment. Because it
involves the insertion of some type of nucleic acid (e.g.,
DNA) fragment, the mutations generated are generally lossof-function, rather than gain-of-function mutations. However, there are several examples of insertions generating gainof-function mutations. Insertion mutagenesis has been very
successful in bacteria and Drosophila.
[0229] Transposable genetic elements are DNA sequences
that can move (transpose) from one place to another in the
genome of a cell. The first transposable elements to be recognized were the Activator1Dissociation elements of Zea
mays. Since then, they have been identified in a wide range of
organisms, both prokaryotic and eukaryotic.
[0230] Transposable elements in the genome are characterized by being flanked by direct repeats of a short sequence of
DNA that has been duplicated during transposition and is
called a target site duplication. Virtually all transposable elements whatever their type, and mechanism of transposition,
make such duplications at the site of their insertion. In some
cases the number of bases duplicated is constant, in other
cases it may vary with each transposition event. Most transposable elements have inverted repeat sequences at their termini. These terminal inverted repeats may be anything from a
few bases to a few hundred bases long and in many cases they
are known to be necessary for transposition.
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(02311 Prokaryotic transposable elements have been most
studied in E. coli and Gram negative bacteria, but also are
present in Gram positive bacteria. They are generally termed
insertion sequences if they are less than about 2 kB long, or
transposons if they are longer. Bacteriophages such as mu and
D108, which replicate by transposition, make up a third type
of transposable element. elements of each type encode at least
one polypeptide a transposase, required for their own transposition. Transposons often further include genes coding for
function unrelated to transposition, for example, antibiotic
resistance genes.
(02321 Transposons can be divided into two classes according to their structure. First, compound or composite transposons have copies of an insertion sequence element at each
end, usually in an inverted orientation. These transposons
require transposases encoded by one of their terminal IS
elements. The second class of transposon have terminal
repeats of about 30 base pairs and do not contain sequences
from IS elements.
[0233] Transposition usually is either conservative or replicative, although in some cases it can be both. In replicative
transposition, one copy of the transposing element remains at
the donor site, and another is inserted at the target site. In
conservativetransposition, the transposing element is excised
from one site and inserted at another.
[0234] Eukaryotic elements also can be classified according to their structure and mechanism of transportation. The
distinction is between elements that transpose via an
RNA intermediate, and elements that transpose directly from
DNA to DNA.
[0235] Elements that transpose via an RNA intermediate
often are referred to as retrotransposons, and their most characteristic feature is that they encode polypeptides that are
believed to have reverse transcriptionase activity. There are
two types of retrotransposon. Some resemble the integrated
proviral DNA of a retrovirus in that they have long direct
repeat sequences, long terminal repeats (LTRs), at each end.
The similarity between these retrotransposons and proviruses
extends to their coding capacity. They contain sequences
related to the gag and pol genes of aretrovirus, suggesting that
they transpose by a mechanism related to a retroviral life
cycle. Retrotransposons of the second type have no terminal
repeats. They also code for gagand
transpose by reverse transcription of RNA intermediates, but
do so by a mechanism that differs from that or retrovirus-like
elements. Transposition by reverse transcription is a replicative process and does not require excision of an element from
a donor site.
[0236] Transposable elements are an important source of
spontaneous mutations, and have influenced the ways in
which genes and genomes have evolved. They can inactivate
genes by inserting within them, and can cause gross chromosomal rearrangements either directly, through the activity of
their transposases, or indirectly, as a result of recombination
between copies of an element scattered around the genome.
Transposable elements that excise often do so imprecisely
and may produce alleles coding for altered gene products if
the number of bases added or deleted is a multiple of three.
[0237] Transposable elements themselves may evolve in
unusual ways. If they were inherited like other DNA
sequences, then copies of an element in one species would be
more like copies in closely related species than copies inmore
distant species. This is not always the case, suggesting that

transposable elements are occasionally transmitted horizontally from one species to another.
[0238] ii) Chemical Mutagenesis.
[0239] Chemical mntagenesis offers certain advantages,
such as the ability to find a full range of mutant alleles with
degrees of phenotypic severity, and is facile and inexpensive
to perform. The majority of chemical carcinogens produce
mutations in DNA. Benzo(a)pyrene, N-acetoxy-2-acetyl
aminofluorene and aflotoxin B1 cause GC to TA transversions in bacteria and mammalian cells. Benzo(a)pyrene also
can produce base substitutions such as AT to TA. N-nitroso
compounds produce GC to AT transitions. Alkylation of the
0 4 position of thymine induced by exposure to n-nitrosoureas results in T.4 to CG transitions.
[0240] A high correlation between mutagenicity and carcinogenity is the underlying assumption behind the Ames test
(McCann et al., 1975) which speedily assays for mutants in a
bacterial system, together with an added rat liver homogenate, which contains the microsomal cytochrome P450, to
provide the metabolic activation of the mutagens where
needed.
[0241] In vertebrates, several carcinogens have been found
to produce mutation in the ras proto-oncogene. N-nitroso-Nmethyl urea induces mammary, prostate and other carcinomas in rats with the majority of the tumors showing a G to A
transition at the second position in codon 12 of the Ha-ras
oncogene. Benzo(a)pyrene-induced skin tumors containA to
T transformation in the second codon of the Ha-ras gene.
[0242] iii) Radiation Mutagenesis.
[0243] The integrity of biological molecules is degraded by
the ionizing radiation. L4dsorptionof the incident energy leads
to the formation of ions and free radicals, and breakage of
some covalent bonds. Susceptibility to radiation damage
appears quite variable between molecules, and between different crystalline forms of the same molecule. It depends on
the total accumulated dose, and also on the dose rate (as once
free radicals are present, the molecular damage they cause
depends on their natural diffusion rate and thus upon real
time). Damage is reduced and controlled by making the
sample as cold as possible.
[0244] Ionizing radiation causes DNA damage and cell
killing, generally proportional to the dose rate. Ionizing radiation has been postulated to induce multiple biological effects
by direct interaction with DNA, or through the formation of
free radical species leading to DNA damage. These effects
include gene mutations, malignant transformation, and cell
killing. Although ionizing radiation has been demonstrated to
induce expression of certain DNA repair genes in some
prokaryotic and lower eukaryotic cells, little is known about
the effects of ionizing radiation on the regulation of mammalian gene expression (Borek, 1985). Several studies have
described changes in the pattern of protein synthesis observed
after irradiation of mammalian cells. For example, ionizing
radiation treatment of human malignant melanoma cells is
associated with induction of several unidentified proteins
(Boothanet al., 1989). Synthesis of cyclinand co-regulated
polypeptides is suppressed by ionizing radiation in rat REF52
cells, but not in oncogene-transformed REF52 cell lines
(Lambert and Borek, 1988). Other studies have demonstrated
that certain growth factors or cytokines may be involved in
x-ray-induced DNA damage. In this regard, platelet-derived
growth factor is released from endothelial cells after irradiation (Witte, et al., 1989).
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[0245] In the present invention, the term "ionizing radiation" means radiation comprising particles or photons that
have sufficient energy or can produce sufficient energy via
nuclear interactions to produce ionization (gain or loss of
electrons). An exemplary and preferred ionizing radiation is
an y-radiation. The amount of ionizing radiation needed in a
given cell generally depends upon the nature of that cell.
Typically, an effective expression-inducing dose is less than a
dose of ionizing radiation that causes cell damage or death
directly. Means for determining an effective amount of radiation are well known in the art.
[0246] In a certain embodiments, an effective expression
inducing amount is from about 2 to about 30 Gray (Gy)
administered at a rate of from about 0.5 to about 2 Gylminute.
Even more preferably, an effective expression inducing
amount of ionizing radiation is from about 5 to about 15 Gy.
In other embodiments, doses of 2-9 Gy are used in single
doses. An effective dose of ionizing radiation may be from 10
to 100 Gy, with 15 to 75 Gy being preferred, and 20 to 50 Gy
being more preferred.
[0247] Any suitable means for delivering radiation to a
tissue may be employed in the present invention in addition to
external means. For example, radiation may be delivered by
first providing a radiolabeled antibody that immunoreacts
with an antigen of the tumor, followed by delivering an effective amount of the radiolabeled antibody to the tumor. In
addition, radioisotopes may be used to deliver ionizing radiation to a tissue or cell.
[0248] iv) In Vitro Scanning Mutagenesis.
[0249] Random mutagenesis also may be introduced (e.g.,
using error prone PCR, See Cadwell and Joyce, 1992). The
rate of mutagenesis may be increased by performing PCR in
multiple tubes with dilutions of templates.
[0250] One particularly useful mutagenesis technique is
alanine scanning mutagenesis in which a number of residues
are substituted individually with the amino acid alanine so
that the effects of losing side-chain interactions can be determined, while minimizing the risk of large-scale perturbations
in protein conformation.
[0251] In recent years, techniques for estimating the equilibrium constant for ligand binding using minuscule amounts
of protein have been developed (See, e.g., U.S. Pat. Nos.
5,221,605 and 5,238,808, hereinincorporatedby reference in
their entireties). The ability to perform functional assays with
small amounts of material can be exploited to develop highly
efficient, in vitro methodologies for the saturation mutagenesis of antibodies. The inventors bypassed cloning steps by
combining PCR mutagenesis with coupled in vitro transcriptionitranslation for the high throughput generation of protein
mutants. Here. the PCR nroducts are used directlv as the
template for the in vitro transcriptionitranslation of the
mutant single chain antibodies. Because of the high efficiency
with which all 19 amino acid substitutions can be generated
and analyzed in this way, it is now possible to perform saturation mutagenesis on numerous residues of interest, a process that can be described as in vitro scanning saturation
mutagenesis (Burks et al., 1997).
[0252] In vitro scanning saturation mutagenesis provides a
rapid method for obtaining a large amount of structure-function information including: (i) identification of residues that
modulate ligand binding specificity, (ii) a better understanding of ligand binding based on the identification of those
amino acids that retain activity and those that abolish activity
at a given location, (iii) an evaluation of the overall plasticity

of an active site or protein subdomain, (iv) identification of
amino acid substitutions that result in increased binding.
[0253] v) Random Mutagenesis by Fragmentation and
Reassmbly.
[0254] A method for generating libraries of displayed
polypeptides is described in U.S. Pat. No. 5,380,721, herein
incorporated by reference in its entirety. The method comprises obtaining polynucleotide library members, pooling
and fragmenting the polynucleotides, and reforming fragments therefrom, performing PCR amplification, thereby
homologously recombining the fragments to form a shuffled
pool of recombined polynucleotides.
b. Site-Directed Mutagenesis
[0255] Structure-guided site-specific mutagenesis represents a powerful tool for the dissection and engineering of
protein-ligand interactions. The technique provides for the
preparation and testing of sequence variants by introducing
one or more nucleotide sequence changes into a selected
DNA.
[0256] Site-specific mutagenesis uses specific oligonucleotide sequences which encode the DNA sequence of the
desired mutation, as well as a sufficient number of adjacent,
unmodified nucleotides. In this way, a primer sequence is
provided with sufficient size and complexity to form a stable
duplex on both sides of the deletion junction being traversed.
For example, a primer of about 17 to 25 nucleotides in length
is preferred, with about 5 to 10 residues on both sides of the
junction of the sequence being altered.
[0257] The technique typically employs a bacteriophage
vector that exists in both a single-stranded and doublestranded form. Vectors useful in site-directed mutagenesis
include vectors such as the MI3 phage. These phage vectors
are commercially available and their use is generally well
known to those skilled in the art. Double-stranded plasmids
are also routinely employed in site-directed mutagenesis,
which eliminates the step of transferring the gene of interest
from a phage to a plasmid.
[0258] In general, one first obtains a single-strandedvector,
or melts two strands of a double-stranded vector, which
includes within its sequence a DNA sequence encoding the
desired protein or genetic element.An oligonucleotideprimer
bearing the desired mutated sequence, syntheticallyprepared,
is then annealed with the single-stranded DNA preparation,
taking into account the degree of mismatch when selecting
hybridizationconditions. The hybridizedproduct is subjected
to DNA polymerizing enzymes such as E. coli polymerase I
(Klenow fragment) in order to complete the synthesis of the
mutation-bearing strand. Thus, a heteroduplex is formed,
wherein one strand encodes the original non-mutated
sequence, and the second strand bears the desired mutation.
This heteroduplex vector is then used to transform appropriate host cells, such asE. coli cells, and clones are selected that
include recombinant vectors bearing the mutated sequence
arrangement.
[0259] Comprehensive information on the functional significance and information content of a given residue of protein can best be obtained by saturation mutagenesis in which
all 19 amino acid substitutions are examined. The shortcoming of this approach is that the logistics of multiresidue saturation mutagenesis are daunting (Warren et al., 1996, Zeng et
al., 1996;Yelton et al., 1995; Hilton et al., 1996). Hundreds,
and possibly even thousands, of site specific mutants must be
studied. However, improved techniques make production and
rapid screening of mutants much more straightforward. See,
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U.S. Pat. Nos. 5,798,208 and 5,830,650, herein incorporated
by reference in their entireties, for a description of "walkthrough" mutagenesis.
[0260] Other methods of site-directed mutagenesis are disclosed in U.S. Pat. Nos. 5,220,007; 5,284,760; 5,354,670;
5,366,878; 5,389,514; 5,635,377; and 5,789,166, herein
incorporated by reference in their entireties.
[0261] In some embodiments, a variant (e.g., a mutant)
includes "nonconservative" changes (e.g., replacement of a
glycine with a tryptophan). Analogous minor variations can
also include amino aciddeletions or insertions, or both. Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological
activity can be found using computer programs (e.g.,
LASERGENE software, DNASTAR Inc., Madison, Wis.).
[0262] vi. Directed Evolution.
[0263] In some embodiments, variants or other nucleic acid
molecules of interest, may be produced by methods such as
directed evolution or other techniques for producing combinatorial libraries of variants. The synthesis of degenerate
oligonucleotides is well known in the art (See e.g., Narang,
Tetrahedron Lett., 39:39 (1983); Itakura et al., Recombinant
DNA, in Walton (ed.), Proceedings of the 3rd Cleveland Symposium on Macromolecules, Elsevier, Amsterdam, pp 273289 (1981); Itakura et al., Annu. Rev. Biochem., 53:323
(1984); Itakura et al., Science 198:1056 (1984); Ike et al.,
Nucl. Acid Res., 11:477 (1983), herein incorporated by reference in their entireties). Such techniques have been
employed in the directed evolution of proteins (See e.g., Scott
et al., Science 249:386 (1980); Roberts et al., Proc. Natl.
Acad. Sci. USA 89:2429 (1992); Devlin et al., Science 249:
404 (1990); Cwirla et al., Proc. Natl.Acad. Sci. USA 87: 6378
(1990); each of which is herein incorporated by reference; as
well as U.S. Pat. Nos. 5,223,409, 5,198,346, and 5,096,815;
each of which is incorporated herein by reference).
EXPERIMENTAL
[0264] The following examples are provided in order to
demonstrate and further illustrate certain preferred embodiments and aspects of the present invention and are not to be
construed as limiting the scope thereof.
Example 1
Lithographic Methods and Materials for Generating
Transfection Cell Arrays
[0265] Cells. Estrogen receptor (ER)-positive MCF-71
WS8 mammary carcinoma cells, clonally derived from
MCF-7 cells by selection for sensitivity to growth simulation
by 17-P-estradiol (E,) (See, e.g., Jiang et al., 1992. Mol Cell
Endocrinol90(1):77-86' Levenson and Jordan, 1997. Cancer
Res 57(15):3071-a), were utilized. Cells were cultured in
fully estrogenized, phenol red-containing RPMI-1640 media
supplemented with 10% fetal bovine serum (FBS), 100 pM
non-essential amino acids, 100units antibioticlantimycotic, 2
mM L-glutamine, and 6 nglml insulin and maintained at 37'
C. in a humidified 5% CO, atmosphere. Prior to transfecting
cells for an experiment, cells were cultured under estrogenfree conditions by substituting phenol red-free RPMI-1640
and dextran-coated charcoal-treated fetal bovine serum in the
medium. For experiments in which transfected cells were
assayed in 24-well plates using a luminometer, or imaged in
arrays using a CCD camera, cells were cultured under estrogen-free condition for 4 days or 18 h, respectively, prior to

seeding. Culture in estrogen-free media for either time period
allowed adequate time for upregulation of ER protein levels
due to E, withdrawal, while the shorter culture period
enhanced cell viability in the array. All media and media
components were purchased from GIBCOIINVITROGEN
(Carlsbad, Calif.).
[0266] Plasmids. Plasmids were purified from bacteria culture using QIAGEN (Valencia, Calif.) reagents and stored in
Tris-EDTA buffer solution (10 mM Tris, 1 mM EDTA, pH
7.4)) or water at -20' C. Plasmid pEGFP-LUC encodes both
the enhanced green fluorescent protein (EGFP) and firefly
luciferase protein, under the direction of a CMV promoter
(CLONTECH, Mountain View, Calif.). Plasmid pLUC
encodes the firefly luciferase gene in the pNGVLl (National
Gene Vector Labs, University of Michigan) vector backbone
with a CMV promoter. Estrogen-responsive plasmid pERE
(3 X)TK-ffLUC (See, e.g., Catherino and Jordan, 1995. Cancer Lett 92(1):39-47) contains three tandem copies of the
palindromic estrogen response element (ERE) sequence,
placed upstream of a minimal herpes simplex thymidine
kinase (TK) promoter, directing expression of the firefly
luciferase coding sequence in response to transcriptional activation by estradiol (E,)-bound ERu, followed by recruitment
of cofactor complexes and basal transcriptional machinery.
PlasmidpTK-rLUC (phRL-TK, PROMEGA, Madison, Wis.)
contains the minimal TK promoter driving expression of a
humanized renilla luciferase and was used for normalization
of the firefly luciferase plasmids. Plasmid pPGAL encodes
for nuclear-targeted P-galactosidase in the pNGVLl (National Gene Vector Labs, University of Michigan) vector
backbone with a CMV promoter and was used for control
spots on the array.
[0267] DNA complex formation. DNA complexes were
formed with LIPOFECTAMINE 2000 (INVITROGEN,
Carlsbad, Calif.), LIPOFECTAMINE LTX (INVITROGEN,
Carlsbad, Calif.) or EFFECTENE (QIAGEN, Valencia,
Calif.), following manufacturer's instructions. Briefly, for
both LIPOFECTAMINE 2000 and LIPOFECTAMINE LTX,
DNA complexes were formed at a DNA:lipid ratio of 1:2 in
serum-free, OPTI-MEM media (INVITROGEN, Carlsbad,
Calif.), by adding transfection reagent diluted in media dropwise to DNA in media, mixing by gentle pipeting, and then
incubating for 20 minutes. EFFECTENE complexes were
formed by diluting DNA into EC buffer, to which the
Enhancer buffer was added at a DNA to Enhancer ratio of 1:8.
After 2-5 minutes of incubation at room temperature, the
EFFECTENE transfection reagent was then added to the
DNMEnhancer mixture at a DNA to Transfection reagent
ratio of 1:4. After incubation at room temperature for 10
minutes, complexes were diluted with serum-free media
before addition to surfaces or cells. DNA in complexes containing multiple plasmids was extensively mixed prior to
complex formation. For induction studies in estrogen-free
media, phenol red-free OPTI-MEM media was used for complex formation.
[0268] Multiwell dish format reporter gene assays. Multiwell dish format reporter gene assays were performed (e.g., to
compare the ability of surface delivery of complexes to monitor ERu response with traditional bolus delivery). For surface
delivery, the surface of wells of a 24-well plate (BECTON
DICKINSON, Franklin Lakes, N.J.) were serum-coated by
incubation with dextran-coated charcoal-stripped FBS (10%
in 1 XPBS, pH 7.4,380 pL) for 18 hours at 4" C., followed by
two wash steps with PBS (See, e.g., Bengali et al., 2005
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Biotechnol Bioeng 90(3):290-302). Complexes were then
immobilized following complex formation, as described
above, by incubation of DNA complexes (475 pL) with the
serum-coated wells for 2 hours. After complex incubation,
the wells were washed twice with OPTI-MEM (for LIPOFECTAMINE 2000 complexes) or EC buffer (for EFFECTENE comvlexes~and 250.000 MCF-7 cells (cultured in estrogen-free media for 4 days) were seeded onto the immobilized
DNA-lipid complexes in each well.
[0269] For bolus delivery, MCF-7 cells cultured in estrogen-free media for 4 days were seeded in estrogen-free
medium into 24-well plates at densities of 125,000 cells per
well. Eighteen hours later, complexes formed as described
above were diluted in antibiotic-free, estrogen-free media and
then added to the cells.
[0270] For both surface and bolus delivery, complexes contained both the pERE(3 X)TK-ffLUC plasmid and the normalization plasmid, pTK-rLUC, at a ratio of 4: 1. Total DNA
amourfts added for surface delivery ranged from 0.13-1.32
pglcm (0.25-2.5 pg per well) and 0.05-0.26 pg/cm2 (0.0250.5 pg per well) for bolus delivery. Given binding profiles,
these ranges result in approximately the same amount of
DNA bound to the surface as delivered as a bolus (See, e.g.,
2005, Biotechnol Bioeng 90(3):290-302).
[0271] Immediately after complex addition for bolus delivery and 4 hours after cell seeding for surface delivery, cells
were treated with combinations of E, (SIGMA-ALDRICH,
St. Louis, Mo.), the complete anti-estrogen fulvestrant
(FUL), also termed ICI 182,780, TOCRIS Bioscience, Ellisville, Mo.) or vehicle controls. E, and FUL were both dissolved in ethanol and diluted in estrogen-free media to obtain
the indicated concentrations (10- to 1OP9Mfor E,; 1OP6M
for FUL) prior to addition to cells. Ethanol diluted in estrogen-free media served as the vehicle control. Cells were harvested and assayed for firefly and renilla luciferase reporter
gene activities 48 hours after transfection using the DualLuciferase Reporter assay system (PROMEGA, Madison,
Wis.). In this dual-luciferase system, firefly and renilla
luciferases are measured sequentially, in a single well. These
measurements are accomplished by adding the firefly
luciferase substrate first. measuringu luminescence. and then
adding reagents that quench the firefly luciferase reaction and
simultaneously provide the renilla luciferase substrate, followed by measuring renilla luciferase activity. The dual-luciferase assays were carried out using an automated microplate luminometer equipped with dual-injection ports
(MITHRAS LB 940, Berthold Technologies, Oak Ridge,
Tenn.). Relative dual-luciferase activity was calculated by
dividing the luminescent signal from the firefly reporter gene
by the renilla luminescent signal.
[0272] Array fabrication. Soft lithography techniques were
used to pattern DNA complex deposition. A polydimethylsiloxane (PDMS) mold was fabricated by curing PDMS into
thin, flat disks. Briefly, PDMS was prepared in a 10:1 (v:v)
ratio of Silicone Elastomer-184 and Silicone Elastomer Curing Agent-1 84 (SYLGARD 184, DOW CORNING, Midland,
Mich.) by mixing the base and curing agent at least 50 times
using a syringe mixing system. After allowing all air bubbles
to escape, the PDMS was poured directly into a polystyrene
tissue culture dish (100 mm, Corning, Corning, N.Y.) and
cured at 60' C. for approximately 2 hours. The cured PDMS
was removed from the dish and rods of precise diameters
were thenused to punch holes into the PDMS, with diameters
of 2.4 mm. The PDMS mold was rinsed in 70% ethanol,

oxidized using oxygen plasma and then reversibly sealed to
sterile polystyrene microscope slides (NUNC, Rochester,
N.Y.), which were fitted into custom-fabricated TEFLON
slide holders that are rinsed in 70% ethanol before use. The
holes in the PDMS mold, termed microwells, served as reservoirs for deposition of DNA complexes onto the polystyrene slide. After 2 hours of complex deposition in humid
conditions, the PDMS mold was peeled away from the polystyrene, and the slide was rinsed thoroughly with OPTIMEM. For all array studies, DNA concentrations ranged from
0.007 pg/pL to 0.021 pg/pL, with 2.2 pL to 4 pL of complex
volume added to the microwells of the PDMS mold.
[0273] To visualize DNA complex immobilization on the
array and verify deposition replicated the pattern of the
microwells in the PDMS mold, plasmid (pEGFP-LUC) was
labeled with tetramethyl rhodamine (LABEL IT Nucleic
Acid Labeling Kit, MIRUS, Madison, Wis.), complexed as
describedabove, and depositedin the microwells. After deposition, PDMS removal and rinsing, the resulting spots were
visualized with fluorescence microscopy.
[0274] Transfection of cells on the array was verified by
depositing complexes formed with plasmid pEGFP-LUC in
the microwells, and imaging with fluorescence microscopy.
After complex deposition, PDMS removal and rinsing,
MCF-7 cells were seeded onto the slide at a density of lo6
cells per slide (18.75 cm2). Transfection was analyzed after
24 and 48 hours and characterized through GFP expression.
Transfected cells were visualized using an epifluorescence
microscope (LEICA; Bannockbum, Ill.) with a FITC filter
and equipped with a digital camera. Transfection, as assayed
through bioluminescence imaging, was verified by depositing complexes containing both pLUC and pTK-rLUC plasmids at a 1:l ratio. After deposition, PDMS removal and
rinsing, cells were seeded as described above. Transfection
was analvzed after 24 hours and characterized bv dual-luciferase expression through light emission.
[0275] For induction studies in the array, complexes
formed with different plasmids were immobilized in different
spots of the array, in triplicate. Briefly, complexes were
formed with pLUC, pERE(3 X)TK-ffLUC, pERE(3 X)TKffLUC and pTK-rLUC (2:l ratio), or pPGAL. After deposition, PDMS removal and rinsing, MCF-7 cells that had been
cultured in estrogen-free media for 18 hours were seeded in
estrogen-free medium on arrays at a density of lo6 cells per
slide. Immediately after cell seeding, cells were treated with
combinations E,, FUL, or vehicle control, as described
above. Dual-luciferase levels were analyzed 24 hours later by
bioluminescence imaging.
[0276] Bioluminescence imaging. Expression of both
luciferase reporter genes was assessed through imaging of
light production upon sequential addition of the luciferase
substrates to the bulk media. Bioluminescence imaging of the
array was performed using an IVIS imaging system (XENOGEN Corp., Alameda, Calif.), which utilizes a cooled CCD
camera. For imaging, a modified renilla luciferase substrate,
VIVIREN (Promega, Madison, Wis.), was diluted to 0.66
mM in serum-containing media and then added to the arrays
at a final concentration of 10 pM. After 2 minutes, the arrays
were placed into a light-tight chamber and bioluminescence
images were acquired for a total exposure time of 1 minute.
Immediately following imaging with VIVIREN, 1 mM of
luciferase substrate D-luciferin (Molecular Therapeutics Inc.,
MI, 20 mg1mL in PBS), was added into the media above the
cells cultured on the array and bioluminescence images

May 8,2008

acquired 3 minutes later, with 1 minute exposure. Gray scale
and bioluminescence images were superimposed using the
LIVING IMAGE software (XENOGEN Corp., Alameda,
Calif.). A constant size region of interest (ROI) was drawn
overthe spots ofthe array to calculate light signals. The signal
intensity was reported as an integrated light flux (photonsis),
determined by IGOR software (WAVEMETRICS, Lake
Oswego, Oreg.). The signal due to firefly luciferase was determined by subtracting VIVIREN signal from the luciferin
signal. Normalization was accomplished by dividing the firefly luciferase signal (luciferin signal minus VIVIREN signal)
by the renilla luciferase signal (VIVIREN signal). A renilla
signal threshold was set at 3.5E4 photods (2X background)
to distinguish spots of unreliable signals indicating insufficient transfection.
[0277] Statistics. Statistical analysis was performed using
JMP software (SAS Institute, Inc., Cary, N.C.). Comparative
analyses were completed using one-way ANOVA with Tukey
post-tests, at a 95% confidence level. Mean values with standard deviation are reported.
Example 2
Multiwell Dish Format Estrogen Responsive Element (ERE)-Reporter Gene Induction Studies
[0278] Multiwell dish format reporter gene assays were
performed to compare estrogen receptor-alpha (Era)-replated, estrogen response element (ERE)-dependent transcriptional activity in MCF-7 cells transfected via surface-mediated delivery of DNA complexes in comparison to traditional
bolus delivery (See FIG. 1). DNA complexes formedusing an
E,-responsive firefly luciferase reporter plasmid pERE(3 X)
TK-ffLUC and a normalization plasmidpTK-rLUC encoding
renilla luciferase were delivered to cells via bolus or surface
delivery. Transfected cells were treated with various combinations of the agonist E,, the complete antiestrogen FUL, or
ethanol. Surface delivery of the plasmids (See FIG. 1B)
resulted in E,-stimulated responses similar to bolus delivery
(See FIG. lA), with E, statistically inducing firefly luciferase
expression 6-7 fold (p<0.001) over vehicle control or the
addition of FUL. Thus, the present invention provides that the
physiologic state of the cells during surface-mediated delivery allowed the cells to transcriptionally respond to E,. Further, the maximal induction of reporter gene activity was
similar whether the DNA complexes were delivered via bolus
or surface-mediated techniques.
[0279] The amount of transfected plasmid was subsequently investigated, which indicated a similar DNA massdependent effect in reporter gene activity for both surface and
bolus-mediated transfection methods (See FIG. 2). For bolus
delivery (See FIG. 2A), all DNA amounts resulted in significantly different responses (p<0.01), except for 0.1 1 and 0.2
pg/cm2, which were not statistically different from each
other. Maximal induction was achieved at 0.13 pg/cm2 (0.25
pg per well). For surface delivery (See FIG. 2B), all DNA
amounts resulted in significantly different responses (p<O.
05), with 1.05 pg/cm2 (2 pg per well) corresponding to the
highest induction by E,. These results indicate that sufficient
amounts of DNA must be transfected for optimal reporter
gene activitv and excess amounts of DNA lead to less efficient
u
reporter gene activity, possibly due to toxicity, for both delivery methods.
[0280] Assuming that approximately 20% of DNA added
to the cell culture dish surface is immobilized (See, e.g.,

Bengali et al., Biotechnol Bioeng 90(3):290-302) 2005), the
condition with the highest induction (1.05 pg/cm2) would
have presented approximately 0.21 pg/cm2 of DNA to the
cells, which is higher than the bolus condition with the highest induction (0.13 pg/cm2), but still in the range of robust
activity. Therefore, surface delivery required more DNA
added to the surface than what would have been expected
given binding profiles (See, e.g., Bengali et al., Biotechnol
Bioeng 90(3):290-302) 2005). Although an understanding of
the mechanism is not necessary to practice the present invention and the present invention is not limited to any particular
mechanism of action, in some embodiments, the requirement
for more DNA may be due to lower than anticipated binding
efficiencies (-lo%, but still within the range of profiles
reported).
[0281] The specific transfection reagent used to form DNA
complexes and E, concentration responses were subsequently investigated to determine the applicability and sensitivity of the reporter system (See FIG. 3). For LIPOFECTAMINE 2000-DNA complexes (See FIG. 3A),
E,-induction profiles were not significantly different using
bolus versus surface delivery (See FIG. 3A), with E, eliciting
a concentration response from lop1' M to l o p 9M (p<0.05),
and maximal responsiveness observed from lop1' M to
10p9ME, (p>0.05) for bothdelivery methods. For EFFECTENE complexes (See FIG. 3B), bolus delivery resulted in
statistically higher levels of ERE induction (p<0.05) than
surface delivery for all concentrations of E,, except control.
However, the level of ERE induction for surface-mediated
delivery was similar whether complexing DNA with
EFFECTENE (See FIG. 3B) or with LIPOFECTAMINE
2000 (See FIG. 2A). Therefore, the particular transfection
reagent used affected transcriptional activity via the conventional bolus delivery, but not via surface delivery. Thus, the
present invention provides that either EFFECTENE or LIPOFECTAMINE 2000 can be used to delivery plasmid via surface-mediated transfection. Additionally, other transfection
reagents could easily be adapted by one of ordinary skill in the
art for use in surface-mediated delivery.
Example 3
Array Fabrication and Verification
[0282] An array was created using soft lithography techniques to pattern DNA-lipid complex deposition and subsequent transfection upon cell seeding (See FIG. 4). Briefly, a
polydimethylsiloxane (PDMS) mold with microwells (e.g.,
generated as described in Example 1) (See FIG. 4A) was
reversibly sealed to polystyrene microscope slides (See FIG.
4B) with the microwells serving as reservoirs for deposition
of DNA complexes onto the polystyrene slide (See FIG. 4C).
Rhodamine-labeled DNA complexes deposited within
microwells were immobilized to the slide in distinct regions,
replicating the pattern of microwells in the PDMS mold (See
FIG. 4D-F). Transfection of MCF-7 cells seeded onto arrays
of complexes was determined by GFP expression, and was
also confined to the patterns (See FIG. 4G-I).
Example 4
Bioluminescence Imaging of the Array
[0283] Arrays formed with complexes containing plasmids
encoding firefly and renilla luciferase reporter genes (pLUC
and pTK-rLUC) were used to verify the ability of biolumi-
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nescence imaging to detect dual-luciferase expression (See
FIG. 5). Transfectionof MCF-7 cells seededonto these arravs
was assayed after 24 hours by sequentially adding the renilla
and firefly luciferase substrates. Following VIVIREN addition, spot intensities averaged 1.lOX lo5?2.56X lo4 photods (See FIG. 5A), which are similar to signals obtained
with arrays of only pTK-rLUC plasmid. D-Luciferin was
subsequently added to the same array, which was then imaged
to acquire a dual signal (See FIG. 5B), with average spot
intensities of 3.66X 106?4.34x lo5 photods. Firefly
luciferase expression was determined by subtracting the initial VIVIREN signal from the signal obtained through imagD-luciferin. Firefly expression averaged
ing wit)
3.55 X 10 ? 4 . 3 0 ~lo5 photods, also similar to intensities
obtained with arrays formed with only rLUC plasmid. After
normalization, the firefly luciferase signal was 34?8 fold
greater than the respective renilla expression. Timecourse
studies revealed that the VIVIREN signal remained constant
for 10 minutes after substrate addition. Therefore, the present
invention provides that the firefly luciferase signal can be
obtained using a dual imaging strategy (e.g., as described
herein) followed by subtraction techniques (e.g., since imaging can be accomplished within 10 minutes of VIVIREN
addition. The present invention also provides that bioluminescence imaging is able to sensitively capture both
luciferase signals, thereby enabling the same cell population
to be analyzed for the expression of multiple reporter genes.
Example 5
Array Format ERE-Reporter Gene Induction Studies

umn 4) resulted in higher signal intensities in the presence of
luciferin than cells transfected with only the pERE(3 X)TKffLUC (See FIG. 6B, column 3), as there was no carryover of
VIVIREN signal in the latter spots of transfected cells without pTK-rLUC. For E, addition to the array, signal intensities
with luciferin increased as compared to the control condition
for all cells transfected with pERE(3 X)TK-ffLUC plasmids
(See FIG. 6D, columns 3 and 4), indicating ERu-dependent
transcriptional activation of the ERE-regulated plasmid.
Expression of the pLUC plasmid was largely unaffected by
E2(See FIG. 6D, column 1).Additionof the antiestrogenFUL
to the arrays completely eliminated the signal in cells transfected withpERE(3 X)TK-ffLUC alone (See FIG. 6F, c o l u
3), or substantially reduced signal intensities in cells transfected with both pERE(3 X)TK-ffLUC and pTK-rLUC (See
FIG. 6F, c o l u 4), in which the luminescence that was
detected was again due to carryover of the VIVIREN signal.
Therefore, addition of lop6 M FUL led to a complete blockade of ERu-stimulated activity by lop9 M E,. pLUC expression was also lowered in the presence of FUL (See FIG. 6F,
c o l u 1) indicating that some transcriptional elements in the
CMV may be indirectly regulated by ERu, possibly by ERu
tethering to AP1 and SP1 proteins bound directly to DNA in
this promoter.
[0286] Average renilla luminescence intensities in cells
transfected with pERE(3 X)TK-ffLUC and pTK-rLUC plasmids (See FIG. 6A, C, E, c o l u 4) were similar in control
and E, +FUL treated cells, but lower in E, alone treated cells.
Although an understanding of the mechanism is not necessary to practice the present invention and the present invention is not limited to any
. varticular mechanism of action, in
some embodiments, lower renilla luciferase activity is due to
competition for transcriptional cofactors between the ERE
(3 X)TK and TK-only regulated promoters. For example,
under E, stimulation conditions, ERu transcriptional coregulators and basal transcriptional machinery may be preferentially recruited to ERE-containing promoters rather than promoters lacking EREs. Hence, in cells treated with E,, may
occur at the TK-renilla luciferase promoter due to titrating out
of limiting transcription factors.
[0287] Induction of the ER-regulated plasmid system in the
array mimicked results obtained through traditional assay
methods. Firefly luciferase expression was determined by
subtracting the VIVIREN signal from the signal obtained
through imaging with D-luciferin, which was then normalized by the VIVIREN signal (See FIG. 6G). For cells transfected with both the pERE(3 X)TK-ffLUC and pTK-rLUC
plasmids (See FIG. 6, column 4), E, statistically induced
dual-luciferase activity 10-fold (p<0.001) over control or
FUL conditions (See FIG. 6G). Thus, the present invention
provides that the arrays described herein can accurately
report activity of the ERu transcription factor. The concentration response of E, was examined to determine the sensitivity of the reporter system in an array format (See FIG. 7).
For arrays with spots containing both the pERE(3X)TKffLUC and pTK-rLUC plasmids, increasing the concentration of E, statistically increased the induction of firefly
luciferase expression (p<0.05), capturing the concentrationresponse of E, in the induction of this plasmid system.
A

[0284] In order to assess the ability of the arrays to monitor
induction of ERu transcriptional activity (See FIG. 6), complexes formed with different plasmids were immobilized as
an array as follows: 1. pLUC; 2. no DNA (mock); 3. pERE
(3 X)TK-ffLUC; 4. pERE(3 X)TK-ffLUC and pTK-rLUC
(2:l ratio); and 5. pPGAL. Cells seeded on the arrays were
treated with combinations of ethanol control (See FIG.
6A-B), l o p 9 ME, (See FIG. 6C-D), or l o p 9 M E,+ l o p 6 M
FUL (See FIG. 6E-F). Dual-luciferase levels were analyzed
24 hours later using bioluminescence imaging, by first imaging with VIVIREN (See FIG. 6A, C, E), and then imaging
each array with D-luciferin (See FIG. 6B, E, F). Renilla
luciferase activity was only detected in cells transfected with
pTK-rLUC plasmid (See FIG. 6A, C, E, column 4), andnot in
cells transfected with only firefly luciferase-encoding plasmids (See FIG. 6A, C, E, c o l u s 1 and 3), a control PGALencoding plasmid (See FIG. 6A, C, E, column 5) or no DNA
(See FIG. 6A, C, E, column 2). Accordingly, firefly luciferase
activity was only detected in cells transfected with pLUC
(See FIG. 6B, D, F, column 1) or pERE(3 X)TK-ffLUC (See
FIG. 6B, D, F, columns 3 and 4), but not in mock or PGAL
control transfectedcells (See FIG. 6B, D, F, columns 2 and 5).
These results verify the specificity of renilla and firefly
luciferase detection in this system.
[0285] Firefly luciferase activity was detected at substantially higher levels in cells transfected with pERE(3 X)TKffLUC and treated with E, (See FIG. 6D, columns 3 and 4)
compared to those treated with ethanol (See FIG. 6B, columni 3 and 4) or E,+FUL (See FIG. 6 F, columns 3 and 4).
In control-treated arrays, spots of highest intensity were visualized for pLUC (See FIG. 6B, column I), given its highly
active CMV promoter. Cells transfected with both the pERE
(3 X)TK-ffLUC and pTK-rLUC plasmids (See FIG. 6B, col-

Example 6
Three Dimensional Transfected Cell Arrays
[0288] Experiments conducted during development of
some embodiments of the present invention were performed
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to determine cell viability after encapsulation within a threedimensional matrix, alginate. Alginate is a naturally occurring polymer produced by brown algae and has the ability to
ionically crosslink in the presence of divalent cations (See,
e.g., Gombotz and Wee 1998 Advanced Drug Delivery
Reviews 31(3): 267-285). Cell encapsulation begins by mixing cells into a solution containing a concentration of alginate. Using a syringe, the solution is added dropwise to a 40
mM CaCl, and 150mMNaCl solution.After a short period of
time (e.g., 2-3 minutes) the alginate gels to form small beads,
which can then be removed and placed into cell media. The
present invention provides that this process is relatively mild,
providing a gentle environment for cell growth and proliferation. FIG. 8 shows a phase image of MCF-7 cells encapsulated within alginate beads. The cells were stained with MTT,
testing for cell viability (Live cells appear darkly stained).
The present invention provides that almost all cells remain
viable after 2 days of encapsulation.
[0289] A suspended solution of complexes composed of
DNA plasmids and a cationic polymer was added to the
alginatelcell solution prior to gelation. The cationic polymer,
polyethyleimine (PEI), contains positively charged imine
groups that neutralize the DNA's negatively charged phosphate backbone. Thus, in some embodiments, the neutralization allows the polymer to act as a delivery agent, facilitating
transport of the DNA across the cell membrane and to the
nucleus, thereby enhancing gene transfer. The present invention provides that by varying the PEI and DNA concentrations
it is possible to control the nitrogen to phosphate (N:P) ratio
to obtain a charge balance for optimal DNA transfection.
[0290] Complex suspension involved the addition of PEI to
a solution containing a plasmid encoding a beta-galactosidase
reporter gene. MCF-7 cells were added to the complex solution, mixed thoroughly and then this solution was added to an
alginate solution. Beads were formed, placed in media and
stained for beta-galactosidase transfection 1, 2, 3 and 4 days
after initial incubation. This procedure was performed for
1.5% alginate beads with complexes varying in N:P ratios
from 5-100, as shown in FIG. 9 a . An N:P ratio of around 25
consistently gave the highest percent transfection efficiency.
Using an N:P ratio of 25, transfection efficiency as a function
of DNA concentration was characterized in which a maximum appeared to be reached at 12 pglml given a cell concentration of 250,000 cellslml (See FIG. 2b). FIG. 10 shows
phase imaging for alginate beads containing 12 pglml DNA in
comvlexes with an N:P ratio of 25 and cell concentration of
250,000 cellslml (See FIG. 10c at a lower magnification).The
present invention provides, as determined by beta-galactosidase staining, a transfection efficiency of 70-90% was
obtained counting only stained cells.
[0291] Using these optimized conditions an array of alginate and alginatelcollagen beads was formed, encapsulating a
mixture of MCF-7 cells and P-Luc-DNMPEI complexes, PLuc-DNA being plasmid containing the luciferase reporter
gene. Briefly, MCF-7 cells were added to a solution of suspended complexes composed of PEI and plasmids encoding a
luciferase reporter gene. The solution was mixed thoroughly
and added to alginate and alginatelcollagen solutions, creating mixtures with final concentrations of 1.5% alginate or
1.5% alginate with 0.2% collagen. Each mixture was then
placed into a separate syringe. With a needle attached, the
alginatelcomplexicel1mixture was added dropwise to glass
coverslips and immediately submerged into a 150 mM NaCl
and 40 mM CaCl, solution. Forming beads on a glass cover-

slip secured the beads to a surface while allowing them to
maintain a 3D hemispherical shape. Gels were analyzed 48
hours later using real-time luciferase imaging. A 1 mM
luciferin solution was added to the media above the array.
Light emission was imaged 3 minutes later with an exposure
time set for 1 min. FIG. 11 shows the expression for both
alginate (top) and alginatelcollagen (bottom) beads. Expression was confined solely to the area containing the gels
[0292] All publications and patents mentioned in the above
specification are herein incorporated by reference. Various
modifications and variations of the described compositions
and methods of the invention will be apparent to those skilled
in the art without departing from the scope and spirit of the
invention.Although the invention has been described in connection with specific preferred embodiments, it should be
understood that the invention as claimed should not be unduly
limited to such specific embodiments. Indeed, various modifications of the describedmodes for carrying out the invention
that are obvious to those skilled in the relevant fields are
intended to be within the scope of the present invention.
1 .A composition comprising a three-dimensional transfection cell array comprising an array of spatially controllable
immobilized gels, wherein said gels comprise a crosslinkable
biopolymer solution comprising cells exposed to transfection
molecules.
2 . The composition of claim 1, wherein the gels are formed
by adding a solution comprising transfection molecules and
cells to an alginate solution, allowing beads to form, and
placing the same within cell growth media.
3 . The composition of claim 2 , wherein said alginate solution comprises alginate and collagen.
4. The composition of claim 3 , wherein said composition
further comprises polyethyleimine (PEI).
5. The composition of claim 3 , wherein the alginate is
present at a final concentration of about 1.5%.
6. The composition of claim 3 , wherein the collagen is
present at a final concentration of about 0.2%.
7. The composition of claim 4, wherein PEI is present in an
amount such that the nitrogen to phosphate ratio is 25.
8 . The composition of claim 1, wherein the transfection
molecules are nucleic acid sequences.
9 . The composition of claim 8 , wherein the nucleic acid
sequences are located within expression vectors.
10. The composition of claim 1, wherein said transfection
molecules comprise a normalization plasmid and a functional
plasmid, wherein the normalization plasmid, comprising a
promoter region and a reporter molecule, allows cellular
transfection efficiency to be normalized over said array.
11. The composition of claim 10, wherein the functional
plasmid comprises a reporter molecule that is different from
the reporter molecule of said normalization plasmid.
12. A method of transfecting cells comprising
a) providing:
i) a composition comprising a biopolymer comprising
alginate and collagen,
ii) transfection molecules, and
ii) cells; and
b) mixing the composition comprising biopolymer, transfection molecules and cells, in the presence of PEI,
under conditions such that beads form; and
c) placing said beads in cell growth media.
13. A method of generating an array, comprising:
a) forming holes in a first material to generate an array
mold,
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b) attaching said array mold to a solid substrate to form a
complex comprising a plurality of wells;
c) depositing first nucleic acidvectors into saidplurality of
wells under conditions such that said first nucleic acid
vectors are generally immobilized on said solid substrate, wherein said first nucleic acid vectors comprise
nucleic acid, and wherein said nucleic acid comprises: 1)
a reporter gene; and 2) a promoter region configured to
bind transcription factors; and
d) removing said array mold from said solid substrate to
generate an array on said solid substrate.
14. The method of claim 13, wherein said first material
comprises PDMS.

15. The method of claim 13, wherein said solid substrate
comprises polystyrene.
16. The method of claim 13, prior to step d) depositing
second nucleic acid vectors into said plurality of wells,
wherein said second nucleic acid vectors comprise nucleic
acid comprising: 1) a second reporter gene; and 2) a promoter
region that allows transfection efficiency to be normalized
over said array.
17. The method of claim 13, wherein said first nucleic acid
vectors are immobilized on said solid substrate such that they
can deliver said nucleic acid to a cell.

